TW201733601A - 包含細菌菌株之組合物 - Google Patents
包含細菌菌株之組合物 Download PDFInfo
- Publication number
- TW201733601A TW201733601A TW106107283A TW106107283A TW201733601A TW 201733601 A TW201733601 A TW 201733601A TW 106107283 A TW106107283 A TW 106107283A TW 106107283 A TW106107283 A TW 106107283A TW 201733601 A TW201733601 A TW 201733601A
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- bacterial strain
- strain
- visceral hypersensitivity
- ibs
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 240
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 171
- 230000009278 visceral effect Effects 0.000 claims abstract description 122
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 107
- 208000026935 allergic disease Diseases 0.000 claims abstract description 99
- 230000009610 hypersensitivity Effects 0.000 claims abstract description 97
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 80
- 241000894006 Bacteria Species 0.000 claims description 60
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 44
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 38
- 241000894007 species Species 0.000 claims description 30
- 230000000813 microbial effect Effects 0.000 claims description 29
- 201000006549 dyspepsia Diseases 0.000 claims description 22
- 208000011231 Crohn disease Diseases 0.000 claims description 19
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 18
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 230000007815 allergy Effects 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- 206010021746 Infantile colic Diseases 0.000 claims description 9
- 210000001072 colon Anatomy 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 8
- 230000036407 pain Effects 0.000 claims description 8
- 241000676207 Brevundimonas faecalis Species 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 210000000664 rectum Anatomy 0.000 claims description 6
- 241000520742 Blautia hydrogenotrophica Species 0.000 claims description 4
- 241000335560 Blautia stercoris Species 0.000 claims description 3
- 241001038648 Blautia wexlerae Species 0.000 claims description 3
- 230000033001 locomotion Effects 0.000 claims description 3
- 241001202853 Blautia Species 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 241000700159 Rattus Species 0.000 description 66
- 230000000694 effects Effects 0.000 description 39
- 210000000936 intestine Anatomy 0.000 description 26
- 239000008194 pharmaceutical composition Substances 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 18
- 230000009467 reduction Effects 0.000 description 18
- 230000002550 fecal effect Effects 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 16
- 241000588655 Moraxella catarrhalis Species 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- 239000002775 capsule Substances 0.000 description 11
- 208000004998 Abdominal Pain Diseases 0.000 description 10
- 244000005709 gut microbiome Species 0.000 description 10
- 150000004666 short chain fatty acids Chemical class 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 9
- 235000013336 milk Nutrition 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- 210000001015 abdomen Anatomy 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 235000021391 short chain fatty acids Nutrition 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 230000019086 sulfide ion homeostasis Effects 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000011552 rat model Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000007901 soft capsule Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 240000007551 Boswellia serrata Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 210000004534 cecum Anatomy 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 230000010339 dilation Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 235000013406 prebiotics Nutrition 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 5
- 230000001332 colony forming effect Effects 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000003305 oral gavage Methods 0.000 description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 5
- 239000004299 sodium benzoate Substances 0.000 description 5
- 235000010234 sodium benzoate Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 208000002881 Colic Diseases 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000001294 Nociceptive Pain Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000005862 Whey Substances 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000009520 phase I clinical trial Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000009935 visceral pain Diseases 0.000 description 4
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 3
- 235000011331 Brassica Nutrition 0.000 description 3
- 241000219198 Brassica Species 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 240000001929 Lactobacillus brevis Species 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 210000000929 nociceptor Anatomy 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- 241000194002 Blautia hansenii Species 0.000 description 2
- 241001464894 Blautia producta Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000605716 Desulfovibrio Species 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010061166 Gastroenteritis bacterial Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 241000194340 Kalmia polifolia Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 101000872823 Xenopus laevis Probable histone deacetylase 1-A Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 2
- 229960004977 anhydrous lactose Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000035568 catharsis Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 235000020186 condensed milk Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000006477 desulfuration reaction Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000021140 nondigestible carbohydrates Nutrition 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008050 pain signaling Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000010845 search algorithm Methods 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- 239000007169 ycfa-medium Substances 0.000 description 2
- 229930195724 β-lactose Natural products 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000247079 Bacteroidales bacterium Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186560 Blautia coccoides Species 0.000 description 1
- 241000335561 Blautia faecis Species 0.000 description 1
- 241001449840 Blautia glucerasea Species 0.000 description 1
- 241000028537 Blautia luti Species 0.000 description 1
- 241000149420 Bothrometopus brevis Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 241000205085 Desulfobacter Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000605980 Faecalibacterium prausnitzii Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910004861 K2 HPO4 Inorganic materials 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 241000084981 Rena humilis Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000858633 Thalassobaculum fulvum Species 0.000 description 1
- 241001024096 Uleiota Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 235000019541 flavored milk drink Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000009279 non-visceral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000019895 oat fiber Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 1
- 229960003040 rifaximin Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000001573 trophoblastic effect Effects 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/09—Other cheese preparations; Mixtures of cheese with other foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/02—Whey; Whey preparations containing, or treated with, microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/005—Condensed milk; Sugared condensed milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G9/363—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Abstract
本發明提供用於治療或預防內臟過敏性之包含一或多種細菌菌株之組合物。
Description
本發明屬包含自哺乳動物消化道分離之細菌菌株之組合物及該等組合物治療疾病之用途的領域。
儘管認為在子宮內時人腸無菌,但出生後其立即暴露於眾多種母體及環境微生物。其後,發生微生物移生及演替之動態時期,該時期受諸如分娩模式、環境、飲食及宿主基因型之因素影響,所有此等因素皆影響腸道微生物區之組成,尤其在幼年期間。隨後,微生物區穩定並變得成人化[1]。人類腸道微生物區含有多於1500種不同的種系型,其中兩種主要細菌門(division)(門(phyla
))之豐度佔優,即擬桿菌門及厚壁菌門[2-3]。由人類腸道之細菌移生引起之成功的共生關係已產生眾多種代謝、結構、保護及其他有益功能。經移生腸道之增強代謝活動確保原本不可消化之飲食組份降解,同時釋放副產物,為宿主提供重要營養源及額外健康益處。類似地,腸道微生物區之免疫重要性係公認的且例示於無菌動物中,該等無菌動物之免疫系統受損且在引入共生性細菌後經功能重構[4-6]。 已記載諸如發炎性腸病(IBD)之胃腸道病症中微生物區組成之巨大改變。舉例而言,在IBD患者中梭菌屬(Clostridium
)群落XIVa及梭菌屬群落XI (普拉梭菌(F.prausnitzii
))細菌之含量降低,而大腸桿菌(E. coli
)之數目增加,此表明腸道內共生生物及致病生物之平衡的轉移[7-11]。 在對某些細菌菌株可對動物腸道具有之潛在正面效應之認識中,已提出多種菌株可用於治療多種疾病(參見,例如[12-15])。已提出多種菌株(主要包括乳酸菌屬(Lactobacillus
)及雙叉桿菌屬(Bifidobacterium
)菌株)可用於治療多種腸病症(綜述參見[16])。亦已提出布勞特氏菌(Blautia
)屬之菌株可用於調節消化生態系統之微生物平衡(WO 01/85187)。然而,對不同細菌菌株與不同疾病之間之關係以及特定細菌菌株對腸道及在全身性層面上及對任何特定類型之疾病的精確效應之表徵很不充分。 需要表徵腸道細菌之潛在效應,使得可開發使用腸道細菌之新穎療法。
本發明者已開發出用於治療並預防內臟過敏性之新穎療法。特定而言,本發明者已鑑別來自布勞特氏菌屬之細菌菌株可有效降低內臟過敏性。如在實例中所闡述,經口投與包含氫營養布勞特氏菌(Blautia hydrogenotrophica
)之組合物可減少內臟過敏性及刺激性腸症候群(IBS)之大鼠模型之內臟過敏性。因此,在第一實施例中,本發明提供包含布勞特氏菌屬之細菌菌株之組合物,其係用於治療或預防內臟過敏性之方法中。 在較佳實施例中,本發明提供包含布勞特氏菌屬之細菌菌株之組合物,其係用於治療或預防經診斷患有克隆氏病(Crohn’s disease)、潰瘍性結腸炎、功能性消化不良或更佳地IBS之個體之內臟過敏性之方法中。在其他較佳實施例中,本發明提供包含布勞特氏菌屬之細菌菌株之組合物,其係用於治療或預防經診斷患有克隆氏病、潰瘍性結腸炎、功能性消化不良、嬰兒腸絞痛或更佳地IBS之個體之內臟過敏性之方法中。 在其他較佳實施例中,本發明提供包含布勞特氏菌屬之細菌菌株之組合物,其係用於治療或預防腹部中、較佳地胃腸道中且最佳地下胃腸道中之內臟過敏性。在其他實施例中,本發明之組合物係用於治療或預防盲腸、結腸或直腸中之內臟過敏性。 在本發明之較佳實施例中,組合物中之細菌菌株屬於氫營養布勞特氏菌。亦可使用緊密相關之菌株,例如具有與氫營養布勞特氏菌之細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列之細菌菌株。較佳地,細菌菌株具有與SEQ ID NO:5至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。最佳地,組合物中之細菌菌株係以登錄號DSM 10507/14294寄存之氫營養布勞特氏菌菌株。 在本發明之其他實施例中,組合物中之細菌菌株屬於糞便布勞特氏菌(Blautia stercoris
)。亦可使用緊密相關之菌株,例如具有與糞便布勞特氏菌之細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列之細菌菌株。較佳地,細菌菌株具有與SEQ ID NO:1或3至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。較佳地,序列一致性係對SEQ ID NO:3而言。較佳地,用於本發明中之細菌菌株具有由SEQ ID NO:3所表示之16s rRNA序列。 在本發明之其他實施例中,組合物中之細菌菌株屬於魏氏布勞特氏菌(Blautia wexlerae
)。亦可使用緊密相關之菌株,例如具有與魏氏布勞特氏菌之細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列細菌菌株。較佳地,細菌菌株具有與SEQ ID NO:2或SEQ ID NO:4至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。較佳地,序列一致性係對SEQ ID NO:4而言。較佳地,用於本發明中之細菌菌株具有由SEQ ID NO:4所表示之16s rRNA序列。 在某些實施例中,本發明之組合物係用於經口投與。經口投與本發明之菌株可有效治療內臟過敏性。而且,經口投與對患者及開業醫師方便,且允許遞送至腸及/或在腸中部分或全部移生。 在某些實施例中,本發明之組合物包含一或多種醫藥上可接受之賦形劑或載劑。 在某些實施例中,本發明之組合物包含已經凍乾之細菌菌株。凍乾係有效且方便的製備允許遞送細菌之穩定組合物之技術,且顯示提供實例中之有效組合物。 在某些實施例中,本發明提供包含如上文所述組合物之食物產品。 在某些實施例中,本發明提供包含如上文所述組合物之疫苗組合物。 另外,本發明提供治療或預防內臟過敏性之方法,其包含投與包含布勞特氏菌屬之細菌菌株之組合物。
細菌菌株
本發明之組合物包含布勞特氏菌屬之細菌菌株。實例顯示,此屬之細菌可用於治療或預防內臟過敏性。較佳細菌菌株屬氫營養布勞特氏菌、
糞便布勞特氏菌及魏氏布勞特氏菌種。
用於本發明中之其他較佳細菌菌株係產生性布勞特氏菌(Blautia producta
)、
球形布勞特氏菌(Blautia coccoides
)及漢遜布勞特氏菌(Blautia hansenii
)。
用於本發明中之布勞特氏菌菌株之實例包括氫營養布勞特氏菌、糞便布勞特氏菌(B. stercoris) 、
糞便布勞特氏菌(B. faecis) 、
球形布勞特氏菌(B. coccoides)
、格魯氏布勞特氏菌(B. glucerasea)
、漢遜布勞特氏菌(B. hansenii)
、陸體布勞特氏菌(B. luti)
、產生性布勞特氏菌(B. producta)
、斯辰氏布勞特氏菌(B. schinkii
)及魏氏布勞特氏菌(B. wexlerae)
。布勞特氏菌種係革蘭氏(Gram)反應陽性、非運動性細菌,其可係球菌狀或卵形且全部皆係產生乙酸作為葡萄糖發酵之主要最終產物之絕對嫌氧菌[17]。布勞特氏菌可自人類腸道分離,但產生性布勞特氏菌係自敗血症試樣分離。 氫營養布勞特氏菌(先前稱為氫營養瘤胃球菌(Ruminococcus hydrogenotrophicus
))已自哺乳動物之腸道分離,嚴格嫌氧並將H2
/CO2
代謝為可對人類營養及健康重要之乙酸鹽。氫營養布勞特氏菌之模式菌株係S5a33 = DSM 10507 = JCM 14656。氫營養布勞特氏菌菌株S5a36之16S rRNA基因序列之基因庫(GenBank)登錄號係X95624.1 (在本文中揭示為SEQ ID NO:5)。此實例性氫營養布勞特氏菌菌株闡述於[17]及[18]中。S5a33菌株及S5a36菌株對應於自健康個體之糞便試樣分離之菌株之兩個子純系。其顯示相同的形態、生理學及代謝並具有相同的16S rRNA序列。因此,在一些實施例中,用於本發明中之氫營養布勞特氏菌具有SEQ ID NO:5之16S rRNA序列。 以登錄號DSM 10507以及以登錄號DSM 14294寄存之氫營養布勞特氏菌細菌在實例中經測試且在本文中亦稱為菌株BH。菌株BH係在1996年1月以登錄號DSM 10507作為「氫營養瘤胃球菌」寄存於Deutsche Sammlung von Mikroorganismen [German Microorganism Collection] (Mascheroder Weg 1b, 38124 Braunschweig,德國),以及在2001年5月10日以登錄號DSM 14294作為「S5a33」寄存。寄存者係INRA Laboratoire de Microbiologie CR de Clermont-Ferrand/Theix 63122 Saint Genès Champanelle, 法國。寄存物之所有權已藉由受讓之方式轉給4D Pharma Plc。 糞便布勞特氏菌菌株GAM6-1T
之16S rRNA基因序列之基因庫登錄號係HM626177 (本文中揭示為SEQ ID NO:1)。實例性糞便布勞特氏菌菌株係揭示於[19]中。魏氏布勞特氏菌之模式菌株係WAL 14507 = ATCC BAA-1564 = DSM 19850 [17]。魏氏布勞特氏菌菌株WAL 14507 T之16S rRNA基因序列之基因庫登錄號係EF036467 (本文中揭示為SEQ ID NO:2)。此實例性魏氏布勞特氏菌菌株係揭示於[17]中。 較佳糞便布勞特氏菌菌株係以登錄號NCIMB 42381寄存之菌株,其在本文中亦稱為菌株830。830菌株之16S rRNA序列係提供於SEQ ID NO:3中。菌株830係在2015年3月12日由GT Biologics Ltd. (Life Sciences Innovation Building, Aberdeen, AB25 2ZS, 蘇格蘭)作為「糞便布勞特氏菌830」寄存於國際寄存機構NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, 蘇格蘭),並被分配登錄號NCIMB 42381。GT Biologics Ltd.隨後將其名稱改為4D Pharma Research Limited。 較佳魏氏布勞特氏菌菌株係以登錄號NCIMB 42486寄存之菌株,其在本文中亦稱為菌株MRX008。MRX008菌株之16S rRNA序列係提供於SEQ ID NO:4中。菌株MRX008係在2015年11月16日由4D Pharma Research Ltd. (Life Sciences Innovation Building, Aberdeen, AB25 2ZS, 蘇格蘭)作為「布勞特氏菌 / 瘤胃球菌 MRx0008
」寄存於國際寄存機構NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, 蘇格蘭),並被分配登錄號NCIMB 42486。 亦預期與實例中所測試菌株緊密相關之細菌菌株有效治療或預防內臟過敏性。在某些實施例中,用於本發明中之細菌菌株具有與氫營養布勞特氏菌之細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列 較佳地,用於本發明中之細菌菌株具有與SEQ ID NO:5至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。 在某些實施例中,用於本發明中之細菌菌株具有與糞便布勞特氏菌之細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。較佳地,用於本發明中之細菌菌株具有與SEQ ID NO:1或SEQ ID NO:3至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。較佳地,序列一致性係對SEQ ID NO:3而言。較佳地,用於本發明中之細菌菌株具有由SEQ ID NO:3所表示之16s rRNA序列。在某些實施例中,用於本發明中之細菌菌株具有與魏氏布勞特氏菌之細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。較佳地,用於本發明中之細菌菌株具有與SEQ ID NO:2或SEQ ID NO:4至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。較佳地,序列一致性係對SEQ ID NO:4而言。較佳地,用於本發明中之細菌菌株具有由SEQ ID NO:4所表示之16s rRNA序列。 亦預期係以登錄號DSM 10507/14294寄存之細菌之生物型或以登錄號NCIMB 42381及NCIMB 42486寄存之細菌之生物型之細菌菌株有效治療或預防內臟過敏性。生物型係具有相同或極相似生理及生物化學特徵之緊密相關之菌株。 係以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌之生物型並適用於本發明之菌株可藉由將以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌之其他核苷酸序列定序來鑑別。舉例而言,實質上全基因體可經定序,且用於本發明中之生物型菌株可跨越其全基因體之至少80% (例如,跨越至少85%、90%、95%或99%或跨越其全基因體)具有至少95%、96%、97%、98%、99%、99.5%或99.9%之序列一致性。舉例而言,在一些實施例中,生物型菌種跨越其基因體之至少98%具有至少98%之序列一致性,或跨越其基因體之99%具有至少99%序列一致性。用於鑑別生物型菌株之其他適宜序列可包括hsp60或諸如BOX、ERIC、(GTG)5
或REP或[20]之重複性序列。生物型菌株可具有與以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌之對應序列具有至少95%、96%、97%、98%、99%、99.5%或99.9%序列一致性之序列。在一些實施例中,生物型菌種具有作為DSM 10507/14294寄存之氫營養布勞特氏菌菌株之對應序列具有至少97%、98%、99%、99.5%或99.9%序列一致性之序列,且包含與SEQ ID NO:5至少99%一致(例如,至少99.5%或至少99.9%一致)之16S rRNA序列。在一些實施例中,生物型菌種具有與作為DSM 10507/14294寄存之氫營養布勞特氏菌菌株之對應序列具有至少97%、98%、99%、99.5%或99.9%序列一致性之序列,且具有SEQ ID NO:5之16S rRNA序列。 或者,係以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌之生物型且適用於本發明之菌株可藉由使用登錄號DSM 10507/14294寄存物、登錄號NCIMB 42381寄存物或登錄號NCIMB 42486寄存物及限制片段分析及/或PCR分析,例如,藉由使用螢光擴增片段長度多型性(FAFLP)及重複性DNA元件(rep)-PCR指紋分析或蛋白質譜分析或部分16S rDNA或23s rDNA定序來鑑別。在較佳實施例中,可使用此等技術來鑑別其他氫營養布勞特氏菌、
糞便布勞特氏菌或魏氏布勞特氏菌菌株。 在某些實施例中,係以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌之生物型且適用於本發明之菌株係當藉由擴增核糖體DNA限制性分析(ARDRA)分析時,例如當使用Sau3AI限制酶時(實例性方法及指導參見(例如) [21])提供與以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌相同之模式之菌株。或者,將生物型菌株鑑別為與以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌具有相同碳水化合物發酵模式之菌株。 可用於本發明之組合物及方法中之其他布勞特氏菌菌株(例如,以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌之生物型)可使用任一適當方法或策略(包括實例中所述之分析)鑑別。舉例而言,用於本發明中之菌株可藉由培養細菌並將其投與大鼠以在擴張分析中測試來鑑別。特定而言,與以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌具有相似生長模式、代謝類型及/或表面抗原之細菌菌株可用於本發明中。可用菌株將具有與DSM 10507/14294、NCIMB 42381或NCIMB 42486菌株相當之微生物區調節活性。特定而言,生物型菌種將引發與實例中所顯示之效應相當之對內臟過敏性模型之效應,該等效應可藉由使用實例中所述之培養及投與方案鑑別。 本發明之尤佳菌株係以登錄號DSM 10507/14294寄存之氫營養布勞特氏菌菌株。此為在實例中測試並顯示有效治療疾病之實例性BH菌株。因此,本發明提供以登錄號DSM 10507/14294寄存之氫營養布勞特氏菌菌株或其衍生物之細胞(例如,分離細胞),其用於療法中,尤其用於本文中所述之疾病。 以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之菌株之衍生物可係子菌株(後代)或自原始菌株培養(亞選殖)之菌株。本發明菌株之衍生物可經修飾(例如,在基因層面上)而不去除生物活性。特定而言,本發明之衍生菌株具治療活性。衍生菌株將具有與原始DSM 10507/14294、NCIMB 42381或NCIMB 42486菌株相當之微生物區調節活性。特定而言,衍生菌株將引發與實例中所顯示之效應相當之對內臟過敏性模型之效應,該等效應可藉由使用實例中所述之培養及投與方案鑑別。DSM 10507/14294菌株之衍生物通常將係DSM 10507/14294菌株之生物型。NCIMB 42381菌株之衍生物通常將係NCIMB 42381菌株之生物型。NCIMB 42486菌株之衍生物通常將係NCIMB 42486菌株之生物型。 提及以登錄號DSM 10507/14294寄存之氫營養布勞特氏菌菌株之細胞時涵蓋與以登錄號DSM 10507/14294寄存之菌株具有相同安全性及治療效能特徵之任何細胞,且本發明涵蓋此等細胞。提及以登錄號NCIMB 42381寄存之糞便布勞特氏菌菌株之細胞時涵蓋與以登錄號NCIMB 42381寄存之菌株具有相同安全性及治療效能特徵之任何細胞,且本發明涵蓋此等細胞。提及以登錄號NCIMB 42486寄存之魏氏布勞特氏菌菌株之細胞時涵蓋與以登錄號NCIMB 42486寄存之菌株具有相同安全性及治療效能特徵之任何細胞,且本發明涵蓋此等細胞。 在較佳實施例中,本發明組合物中之細菌菌株有活力且能夠部分地或全部移生於腸。 治療用途
在較佳實施例中,本發明之組合物係用於治療內臟過敏性。內臟過敏性係特殊類型之疼痛,其特徵為位於腹腔區域,由胸部、骨盆或腹腔內臟(器官)之痛覺感受器活化所致的主觀疼痛知覺。內臟過敏性通常瀰漫且難以定位,且因此與通常較劇烈並更集中之軀體性疼痛形成對比。而且,與軀體性疼痛不同,內臟過敏性通常與特定結構病灶無關聯。內臟痛覺感受器在本質上不同於皮膚及大部分其他非內臟痛覺感受器[22]。 內臟過敏性通常係在腹部經歷,但並非所有腹痛皆係內臟過敏性。相比之下,腹痛具有許多潛在原因且腹痛可係軀體性疼痛、牽涉痛或內臟疼痛。在腹部中,軀體性疼痛可由發炎器官引起且通常劇烈並集中。腹痛可由纖維肌痛引起,其係軀體(皮膚及肌肉)過敏性之病狀。牽涉痛係在遠離患病器官之皮膚位點感受到。 內臟過敏性通常與功能性消化不良及刺激性腸症候群(IBS)相關。然而,並非所有與功能性消化不良及IBS相關之疼痛皆係內臟過敏性。實際上,許多患有IBS之患者亦展現眾多種腹腔部位(背痛、胃灼熱)及非腹腔部位(偏頭痛、性交困難、軀體定位遠離腸道之身體部位中之肌肉疼痛)中之軀體症狀[23]。 在一些實施例中,疾病或病況之發病機制影響腸。在一些實施例中,疾病或病況之發病機制不影響腸。在一些實施例中,疾病或病況之發病機制不侷限於腸。在一些實施例中,治療或預防發生於除腸以外之位點。在一些實施例中,治療或預防發生於腸以及除腸以外之位點。在某些實施例中,疾病或病況係全身性的。 內臟過敏性亦稱為內臟疼痛,且該兩個術語在本文中互換使用。 如實例中所顯示,本發明之細菌組合物可有效降低內臟過敏性。特定而言,本發明之細菌組合物可減少對結腸直腸擴張之反應,該反應係影響許多患者之內臟過敏性之表現。在較佳實施例中,本發明之組合物係用於治療或預防腹部中、較佳地胃腸道中、且最佳地下胃腸道中之內臟過敏性。在其他實施例中,本發明之組合物係用於治療或預防盲腸、結腸或直腸中之內臟過敏性。 在較佳實施例中,本發明之組合物係用於治療或預防與克隆氏病、潰瘍性結腸炎、功能性消化不良、嬰兒腸絞痛或更佳地IBS相關之內臟過敏性。在較佳實施例中,本發明之組合物係用於治療或預防經診斷患有克隆氏病、潰瘍性結腸炎、功能性消化不良、嬰兒腸絞痛或更佳地IBS之個體之內臟過敏性。在較佳實施例中,本發明之組合物係用於在克隆氏病、潰瘍性結腸炎、功能性消化不良、嬰兒腸絞痛或更佳地IBS之治療中治療或預防內臟過敏性。 在較佳實施例中,本發明之組合物係用於治療或預防與克隆氏病、潰瘍性結腸炎、功能性消化不良或更佳地IBS相關之內臟過敏性。在較佳實施例中,本發明之組合物係用於治療或預防經診斷患有克隆氏病、潰瘍性結腸炎、功能性消化不良或更佳地IBS之個體之內臟過敏性。在較佳實施例中,本發明之組合物係用於在克隆氏病、潰瘍性結腸炎、功能性消化不良或更佳地IBS之治療中治療或預防內臟過敏性。在某些實施例中,本發明之組合物係用於治療遭受胃腸道(尤其在結腸或直腸中)脹痛之患者的內臟過敏性。 與IBS及其他腸病狀相關之不適及痛苦之某些態樣可由胃腸道中氣體之過量產生及該等累積氣體之巨大體積引起。例如,不同氣體之體積增加可導致胃積氣。如實例中所顯示,本發明之細菌組合物可有效治療IBS及其他腸病狀之特定態樣-內臟過敏性。不希望受限於任何理論,所觀測到之本發明之細菌組合物對內臟過敏性之效應可與細菌對特定氣體(H2
S)之效應及其對在腸道中合成H2
S之硫酸鹽還原細菌(SRB)之效應相關。H2
S可作為疼痛信號傳導分子起重要作用且在實例中所觀測到之本發明組合物對內臟過敏性之效應可與腸中H2
S產量之減少有關,該H2
S產生可藉由影響疼痛信號傳導促進內臟過敏性,與涉及氣體體積之任何氣脹效應無關。實例顯示本發明之細菌組合物可有效減少SRB並減少H2
S。在一些實施例中,本發明之細菌組合物在盲腸中減少SRB及/或減少H2
S。SRB係利用硫酸鹽還原作用產生能量之嫌氧細菌且SRB之實例包括脫硫弧菌屬(Desulfovibrio
)之成員,且尤其係懶惰脫硫弧菌屬(Desulfovibrio piger
,其係最豐富之種),以及脫硫桿菌屬(Desulfobacter
)、
脫硫蔥球菌屬(Desulfobulbus
)及脫硫腸狀菌屬(Desulfotomaculum
)之成員。 在某些實施例中,本發明之組合物係用於內臟過敏性之治療中減少SRB在胃腸道中之移生。在此等實施例中,組合物較佳可呈細菌培養物之形式。在此等實施例中,組合物較佳可係凍乾物。在某些實施例中,本發明之組合物係用於內臟過敏性之治療中在胃腸道中降低H2
S含量或預防H2
S含量升高。在此等實施例中,組合物較佳可係凍乾物。 在某些實施例中,本發明之組合物係用於內臟過敏性之治療中減少SRB在胃腸道中之移生、群落及/或群體量。在某些實施例中,本發明之組合物係用於內臟過敏性之治療中減少SRB在盲腸中之移生、群落及/或群體量。 在較佳實施例中,本發明之組合物係用於與IBS相關之內臟過敏性的治療中減少SRB在胃腸道中之移生、降低H2
S含量或預防H2
S含量升高。在其他實施例中,本發明之組合物係用於與克隆氏病、潰瘍性結腸炎、功能性消化不良或嬰兒腸絞痛相關之內臟過敏性之治療中、例如與克隆氏病、潰瘍性結腸炎或功能性消化不良相關之內臟過敏性之治療中,減少SRB在胃腸道中之移生、降低H2
S含量或預防H2
S含量升高。 在較佳實施例中,本發明之組合物係用於與IBS相關之內臟過敏性之治療中減少SRB在胃腸道中之移生、群落及/或群體量,降低H2
S含量或預防H2
S含量升高。在其他實施例中,本發明之組合物係用於與克隆氏病、潰瘍性結腸炎、功能性消化不良或嬰兒腸絞痛相關之內臟過敏性之治療中、例如與克隆氏病、潰瘍性結腸炎或功能性消化不良相關之內臟過敏性之治療中,減少SRB在胃腸道中之移生、群落及/或群體量,降低H2
S含量或預防H2
S含量升高。 在較佳實施例中,本發明之組合物係用於腹部中,較佳地胃腸道中,更佳地下胃腸道中、盲腸中、結腸中或直腸中之內臟過敏性之治療中減少SRB在胃腸道中之移生、降低H2
S含量或預防H2
S含量升高。在較佳實施例中,本發明之組合物係用於腹部中,較佳地胃腸道中,更佳地下胃腸道中、盲腸中、結腸中或直腸中之內臟過敏性之治療中減少SRB在胃腸道中之移生、群落及/或群體量,降低H2
S含量或預防H2
S含量升高。 在某些實施例中,本發明之組合物係用於治療、預防或減少SRB在胃腸道中之移生之方法中。在某些實施例中,本發明之組合物係用於治療、預防或減少SRB在胃腸道中之移生、群落及/或群體量之方法中。在某些實施例中,本發明之組合物係用於降低胃腸道中之H2
S含量或預防H2
S含量升高之方法中。 在某些實施例中,本發明之組合物係用於治療(例如)當與健康個體或健康個體之群體相比時,展現或預期會展現其胃腸道中SRB及/或H2
S含量增加之患者。 在某些實施例中,本發明之組合物係用於預防正在接受或已接受抗生素治療或正在遭受或已遭受細菌胃腸炎之個體之內臟過敏性。抗生素治療及細菌胃腸炎與腸道微生物區之改變相關,該微生物區改變可引發內臟過敏性且可藉由本發明之組合物預防。本發明之組合物可與抗生素治療同時投與。 在較佳實施例中,利用本發明之組合物治療導致降低內臟過敏性、減少SRB移生及/或減少H2
S含量。 治療或預防內臟過敏性可指(例如)緩和症狀嚴重性或減小惡化頻率或對於患者成問題之觸發因素之範圍。舉例而言,在一些實施例中,本發明之組合物係用於治療或預防嚴重的內臟過敏性。在一些實施例中,患有嚴重內臟過敏性之個體係經診斷患有克隆氏病、潰瘍性結腸炎、功能性消化不良、嬰兒腸絞痛或更佳地IBS之個體。在一些實施例中,患有嚴重內臟過敏性之個體係經診斷患有克隆氏病、潰瘍性結腸炎、功能性消化不良或更佳地IBS之個體。 投與模式
較佳地,欲將本發明之組合物投與胃腸道,以使得能將本發明之細菌菌株遞送至腸及/或在腸中部分或全部移生。一般而言,本發明之組合物係經口投與,但其可經直腸、鼻內或經頰或舌下途徑投與。 在某些實施例中,本發明之組合物可作為發泡體、作為噴霧劑或凝膠投與。 在某些實施例中,本發明之組合物可作為栓劑(例如,直腸栓劑),例如以可可油(可可脂)、合成硬脂(例如,suppocire、witepsol)、甘油-明膠、聚乙二醇或甘油皂組合物之形式投與。 在某些實施例中,本發明之組合物係經由以下途徑投與胃腸道:管,例如,鼻胃管、口胃管、胃管、空腸造口管(J管)、經皮內視鏡胃造口術(PEG);或埠,例如提供通路至胃之胸壁埠、空腸埠及其他適宜輸液埠。 本發明之組合物可投與一次,或其可作為治療方案之部分依序投與。在某些實施例中,本發明之組合物欲每天投與。實例顯示,每天投與在內臟過敏性之大鼠模型中成功地提供移生及臨床益處。 實例亦顯示,BH投與可不導致腸中之永久移生,故定期投與延長時間段可提供較大治療益處。因此,實例顯示遵循每天投與將本發明之細菌菌株成功地遞送至結腸。 因此,在某些實施例中,本發明之組合物係定期(例如,每天、每兩天或每週)投與延長時間段(例如,至少一週、兩週、一個月、兩個月、六個月或一年)。 在一些實施例中,本發明之組合物係投與7天、14天、16天、21天或28天或不多於7天、14天、16天、21天或28天。舉例而言,在一些實施例中,本發明之組合物係投與16天。 在本發明之某些實施例中,本發明之治療伴隨患者之腸道微生物區之評價。若未達成本發明菌株之遞送及/或部分或全部移生,使得觀測不到效能,則可重複治療;或若遞送及/或部分或全部移生成功且觀測到效能,則可停止治療。 在某些實施例中,本發明之組合物可投與懷孕動物(例如,哺乳動物,例如人類),以預防其子代在子宮內及/或出生後發生內臟過敏性。 本發明之組合物可投與已經診斷患有內臟過敏性或與內臟過敏性相關之疾病或病況或已鑑別為正處於內臟過敏性之風險下之患者。組合物亦可作為預防性措施投與以防止健康患者發生內臟過敏性。 本發明之組合物可投與已經鑑別為具有異常腸道微生物區之患者。舉例而言,患者可具有減少或不存在之布勞特氏菌、且尤其氫營養布勞特氏菌、糞便布勞特氏菌或魏氏布勞特氏菌之移生。
本發明之組合物可作為諸如營養補充劑之食物產品投與。 一般而言,本發明之組合物係用於治療人類,但其可用於治療動物,包括單胃哺乳動物,例如家禽、豬、貓、狗、馬或兔。本發明之組合物可用於促進動物之生長及表現。若投與動物,則可使用經口胃管灌食。 在一些實施例中,欲向其投與組合物之個體係成年人。在一些實施例中,欲向其投與組合物之個體係人類嬰兒。 組合物
一般而言,本發明之組合物包含細菌。在本發明之較佳實施例中,組合物係以冷凍乾燥形式調配。舉例而言,本發明之組合物可包含包含本發明細菌菌株之顆粒或明膠膠囊,例如硬明膠膠囊。 較佳地,本發明之組合物包含經凍乾之細菌。細菌之凍乾係公認程序且相關指導可在(例如)參考文獻[24-26]中獲得。實例顯示,凍乾物組合物尤其有效。在較佳實施例中,本發明之組合物包含經凍乾之細菌且係用於治療與IBS相關之內臟過敏性、較佳用於在與IBS相關之內臟過敏性之治療中降低H2
S含量或預防H2
S含量升高。在其他較佳實施例中,本發明之組合物包含經凍乾之細菌且係用於治療與IBS相關之內臟過敏性、較佳用於在內臟過敏性之治療中減少SRB在胃腸道中之移生。在其他較佳實施例中,本發明之組合物包含經凍乾之細菌且係用於治療與IBS相關之內臟過敏性、較佳地用於在內臟過敏性之治療中減少SRB在胃腸道中之移生、群落及/或群體量。 或者,本發明之組合物可包含活的活性細菌培養物。實例顯示,本發明之細菌之培養物在治療上有效。 在一些實施例中,本發明組合物中之細菌菌株未經不活化,例如未經熱不活化。在一些實施例中,本發明組合物中之細菌菌株未經殺死,例如未經熱殺死。在一些實施例中,本發明組合物中之細菌菌株未經減毒,例如未經熱減毒。舉例而言,在一些實施例中,本發明組合物中之細菌菌株未經殺死、不活化及/或減毒。舉例而言,在一些實施例中,本發明組合物中之細菌菌株係活的。舉例而言,在一些實施例中,本發明組合物中之細菌菌株有活力。舉例而言,在一些實施例中,本發明組合物中之細菌菌株能部分地或全部移生於腸。舉例而言,在一些實施例中,本發明組合物中之細菌菌株有活力且能夠部分地或全部移生於腸。 在一些實施例中,組合物包含活的細菌菌株及已經殺死之細菌菌株之混合物。 在較佳實施例中,將本發明之組合物囊封以使得能夠將細菌菌株遞送至腸。囊封保護組合物免於降解直至藉助(例如)利用諸如壓力、酶活性或物理分解之化學或物理刺激破裂而遞送於目標位置為止,其可由pH之改變觸發。可使用任何適當囊封方法。實例性囊封技術包括覆埋在多孔基質內、附接或吸附在固體載劑表面上、藉由絮凝或利用交聯劑自聚集及機械密封於微孔性膜或微膠囊後。可用於製備本發明組合物之囊封之指導可在(例如)參考文獻[27-28]中獲得。 組合物可經口投與並可呈錠劑、膠囊或粉末之形式。由於布勞特氏菌係嫌氧菌,故經囊封之產品較佳。可包括其他成分(例如維生素C)作為氧清除劑及益生元受質,以改良在活體內之遞送及/或部分或全部移生及存活。或者,本發明之益生菌(probiotic)組合物可作為食物或營養產品(例如基於乳或乳清之發酵乳製品)或作為醫藥產品經口投與。 可將組合物調配為益生菌。 本發明之組合物包括治療有效量之本發明之細菌菌株。細菌菌株之治療有效量足以發揮對患者之有益效應。細菌菌株之治療有效量可足以導致遞送至患者之腸及/或在患者之腸中部分或全部移生。 例如,對於成年人,細菌之適宜的日劑量可係約1 × 103
至約1 × 1011
菌落形成單位(CFU);舉例而言,約1 × 107
CFU至約1 × 1010
CFU;在另一實例中,約1 × 106
CFU至約1 × 1010
CFU;在另一實例中, 約1 × 107
CFU至約1 × 1011
CFU;在另一實例中,約1 × 108
CFU至約1 × 1010
CFU;在另一實例中,約1 × 108
CFU至約1 × 1011
CFU。 在某些實施例中,細菌之劑量係至少109
個細胞/天,例如至少1010
個細胞/天、至少1011
個細胞/天或至少1012
個細胞/天。 在某些實施例中,相對於組合物之重量,組合物係以約1 × 106
CFU/g至約1 × 1011
CFU/g之量含有細菌菌株;舉例而言,約1 × 108
CFU/g至約1 × 1010
CFU/g。劑量可係(例如) 1 g、3g、5g及10g。 通常,益生菌(例如本發明之組合物)視情況與至少一種適宜的益生元化合物組合。益生元化合物通常係不可消化之碳水化合物(例如,寡醣或多醣或糖醇),其在上消化道中不降解或不吸收。已知益生元化合物包括諸如菊糖及反式半乳寡醣之商品。 在某些實施例中,相對於組合物之總重量,本發明之益生菌組合物以約1重量%至約30重量%之量包括益生元化合物(例如5重量%至20重量%)。碳水化合物可選自由以下組成之群:果寡醣(或FOS)、短鏈果寡醣、菊糖、異麥芽寡醣、果膠、木寡醣(或XOS)、幾丁聚醣-寡醣(或COS)、β-葡聚醣、阿拉伯膠改質的抗性澱粉、聚右旋糖、D-塔格糖、阿拉伯樹膠纖維、刺槐纖維、燕麥纖維及柑橘纖維。在一個態樣中,益生元化合物係短鏈果寡醣(為簡單起見,下文顯示為FOSs-c.c);該FOSs-c.c係不可消化之碳水化合物,通常藉由甜菜糖之轉化獲得且包括鍵結有三個葡萄糖分子之蔗糖分子。 本發明之組合物可包含醫藥上可接受之賦形劑或載劑。此等適宜賦形劑之實例可在參考文獻[29]中發現。用於治療用途之可接受之載劑或稀釋劑為醫藥業內所熟知且闡述於(例如)參考文獻[30]中。適宜載劑之實例包括乳糖、澱粉、葡萄糖、甲基纖維素、硬脂酸鎂、甘露醇、山梨醇及諸如此類。適宜稀釋劑之實例包括乙醇、甘油及水。醫藥載劑、賦形劑或稀釋劑之選擇可針對既定投與路徑及標準醫藥實踐選擇。醫藥組合物可包含任何適宜黏合劑、潤滑劑、懸浮劑、塗佈劑、增溶劑作為載劑、賦形劑或稀釋劑,或除載劑、賦形劑或稀釋劑以外包含任何適宜黏合劑、潤滑劑、懸浮劑、塗佈劑、增溶劑。適宜黏合劑之實例包括澱粉、明膠、天然糖類(例如,葡萄糖、無水乳糖、自由流動乳糖、β-乳糖、玉米甜味劑)、天然及合成膠(例如,阿拉伯樹膠、黃蓍膠或海藻酸鈉)、羧甲基纖維素及聚乙二醇。適宜潤滑劑之實例包括油酸鈉、硬脂酸鈉、硬脂酸鎂、苯甲酸鈉、乙酸鈉、氯化鈉及諸如此類。防腐劑、穩定劑、染料及甚至調味劑可提供於醫藥組合物中。防腐劑之實例包括苯甲酸鈉、山梨酸、半胱胺酸及對羥基苯甲酸之酯,例如,在一些實施例中,防腐劑係選自苯甲酸鈉、山梨酸及對羥基苯甲酸之酯。亦可使用抗氧化劑及懸浮劑。適宜載劑之另一實例係蔗糖。防腐劑之另一實例係半胱胺酸。 本發明之組合物可調配為食物產品。舉例而言,除本發明之治療效應之外,食物產品可提供營養益處,例如在營養補充劑中。類似地,食物產品可經調配以藉由與普通食品而非與醫藥組合物更相似來改善本發明組合物之味道或增強服用組合物之吸引力。在某些實施例中,本發明之組合物經調配為基於乳之產品。術語「基於乳之產品」意指具有不同脂肪含量之任何液體或半固體之基於乳或乳清之產品。基於乳之產品可係(例如)牛乳、山羊乳、綿羊乳、脫脂乳、全脂乳、乳粉與乳清在無任何處理之情況下重新組合之乳或經處理產品,例如酸酪乳、凝結乳、凝乳、酸乳、酸全脂乳、酪乳及其他酸乳產品。另一重要之組包括乳飲料,例如乳清飲料、發酵乳、煉乳、嬰兒或幼兒乳;調味乳、冰淇淋;諸如甜品之含乳食物。 在一些實施例中,本發明之組合物包含一或多種布勞特氏菌屬之細菌菌株且不含有來自任何其他屬之細菌,或其僅包含最少量或生物學上無關量之來自其他屬之細菌。 在某些實施例中,本發明之組合物含有單一細菌菌株或種且不含有任何其他細菌菌株或細菌種。此等組合物可僅包含最少量或生物學上無關量之其他細菌菌株或細菌種。此等組合物可係實質上不含其他物種生物體之培養物。在一些實施例中,此等組合物可係實質上不含其他物種生物體之凍乾物。 在某些實施例中,本發明之組合物包含一或多種布勞特氏菌屬(例如,氫營養布勞特氏菌)之細菌菌株且不含有任何其他細菌屬,或其僅包含最少量或生物學上無關量之來自其他屬之細菌。在某些實施例中,本發明之組合物包含布勞特氏菌之單一種(例如,氫營養布勞特氏菌)且不含有任何其他細菌種,或其僅包含最少量或生物學上無關量之來自其他種之細菌。在某些實施例中,本發明之組合物包含布勞特氏菌(例如,氫營養布勞特氏菌)之單一菌株且不含有任何其他細菌菌株或細菌種,或其僅包含最少量或生物學上無關量之來自另一菌株或種之細菌。 在一些實施例中,本發明之組合物包含一種以上細菌菌株或細菌種。舉例而言,在一些實施例中,本發明之組合物包含一種以上來自同一個種內之菌株(例如,1、2、3、4、5、6、7、8、9、10、15、20、25、30、35、40或45種以上菌株),且視情況不含有來自任何其他種之細菌。在一些實施例中,本發明之組合物包含少於50種來自同一個種內之菌株(例如,少於45、40、35、30、25、20、15、12、10、9、8、7、6、5、4或3種菌株),且視情況不含有來自任何其他種之細菌。在一些實施例中,本發明之組合物包含1-40、1-30、1-20、1-19、1-18、1-15、1-10、1-9、1-8、1-7、1-6、1-5、1-4、1-3、1-2、2-50、2-40、2-30、2-20、2-15、2-10、2-5、6-30、6-15、16-25或31-50種來自同一個種內之菌株,且視情況不含有來自任何其他種之細菌。在一些實施例中,本發明之組合物包含一個以上來自同一屬內之種(例如,1、2、3、4、5、6、7、8、9、10、12、15、17、20、23、25、30、35或40個以上種),且視情況不含有來自任何其他屬之細菌。在一些實施例中,本發明之組合物包含少於50個來自同一屬內之種(例如,少於50、45、40、35、30、25、20、15、12、10、8、7、6、5、4或3個種),且視情況不含有來自任何其他屬之細菌。在一些實施例中,本發明之組合物包含1-50、1-40、1-30、1-20、1-15、1-10、1-9、1-8、1-7、1-6、1-5、1-4、1-3、1-2、2-50、2-40、2-30、2-20、2-15、2-10、2-5、6-30、6-15、16-25或31-50個來自同一屬內之種,且視情況不含有來自任何其他屬之細菌。本發明包含上述之任一組合。 在一些實施例中,組合物包含微生物菌群。舉例而言,在一些實施例中,組合物包含布勞特氏細菌菌株作為微生物菌群之部分。舉例而言,在一些實施例中,布勞特氏細菌菌株係與一或多種(例如,至少2、3、4、5、10、15或20種)來自其他屬之其他細菌菌株(該布勞特氏細菌菌株可與其在活體內共生生存)組合存於腸中。舉例而言,在一些實施例中,組合物包含氫營養布勞特氏菌之細菌菌株與來自不同屬之細菌菌株的組合。在一些實施例中,微生物菌群包含兩個或更多個自單一生物體(例如,人類)之糞便試樣獲得之細菌菌株。在一些實施例中,微生物菌群在自然界中未一起發現。舉例而言,在一些實施例中,微生物菌群包含自至少兩個不同生物體之糞便試樣獲得之細菌菌株。在一些實施例中,該兩個不同生物體來自同一物種,例如兩個不同人類。在一些實施例中,兩個不同生物體係人類嬰兒及成年人。在一些實施例中,兩個不同生物體係人類及非人類哺乳動物。 在一些實施例中,本發明之組合物另外包含與以登錄號DSM 10507/14294寄存之氫營養布勞特氏菌菌株具有相同安全性與治療效能特徵之細菌菌株,但其並非以登錄號DSM 10507/14294寄存之氫營養布勞特氏菌菌株,或其並非係氫營養布勞特氏菌或其並非係布勞特氏菌。 在一些其中本發明之組合物包含一種以上細菌菌株、種或屬之實施例中,個別細菌菌株、種或屬可用於分開、同時或依序投與。舉例而言,組合物可包含所有一種以上細菌菌株、種或屬,或細菌菌株、種或屬可分開儲存並分開、同時或依序投與。在一些實施例中,一種以上細菌菌株、種或屬係分開儲存但在使用前混合在一起。 在一些實施例中,用於本發明中之細菌菌株係自成年人糞便獲得。在一些其中本發明之組合物包含一種以上細菌菌株之實施例中,所有細菌菌株皆係自成年人糞便獲得,或若存在其他細菌菌株,則其僅以最少量存在。細菌可在自成年人糞便獲得並用於本發明之組合物中之後已經培養。 在一些實施例中,一或多個布勞特氏細菌菌株係本發明之組合物中之唯一治療活性劑。在一些實施例中,組合物中之細菌菌株係本發明之組合物中之唯一治療活性劑。 根據本發明使用之組合物可需要或可不需要行銷核可。 在某些實施例中,本發明提供以上醫藥組合物,其中該細菌菌株經凍乾。在某些實施例中,本發明提供以上醫藥組合物,其中該細菌菌株經噴霧乾燥。在某些實施例中,本發明提供以上醫藥組合物,其中細菌菌株經凍乾或噴霧乾燥且其中該細菌菌株係活的。在某些實施例中,本發明提供以上醫藥組合物,其中細菌菌株經凍乾或噴霧乾燥且其中該細菌菌株有活力。在某些實施例中,本發明提供以上醫藥組合物,其中細菌菌株經凍乾或噴霧乾燥且其中該細菌菌株能部分地或全部移生於腸。在某些實施例中,本發明提供以上醫藥組合物,其中細菌菌株經凍乾或噴霧乾燥且其中該細菌菌株有活力並能夠部分地或全部移生於腸。 在一些情形下,經凍乾或噴霧乾燥之細菌菌株在投與之前經重構。在一些情形下,重構係藉由使用本文中所述之稀釋劑進行。 本發明之組合物可包含醫藥上可接受之賦形劑、稀釋劑或載劑。 在某些實施例中,本發明提供醫藥組合物,其包含:本發明之細菌菌株;及醫藥上可接受之賦形劑、載劑或稀釋劑;其中細菌菌株之量在投與需要其之個體時足以治療病症;且其中該病症係內臟過敏性,例如與克隆氏病、潰瘍性結腸炎、功能性消化不良、嬰兒腸絞痛或更佳地IBS相關之內臟過敏性。 在某些實施例中,本發明提供醫藥組合物,其包含:本發明之細菌菌株;及醫藥上可接受之賦形劑、載劑或稀釋劑;其中細菌菌株之量在投與需要其之個體時足以治療病症;且其中該病症係內臟過敏性,例如與克隆氏病,潰瘍性結腸炎,功能性消化不良或更佳地IBS相關之內臟過敏性。 在某些實施例中,本發明提供以上醫藥組合物,其中細菌菌株之量相對於組合物之重量係約1 × 103
菌落形成單位/克至約1 × 1011
菌落形成單位/克。 在某些實施例中,本發明提供以上醫藥組合物,其中該組合物係以1g、3g、5g或10g之劑量投與。 在某些實施例中,本發明提供以上醫藥組合物,其中該組合物係藉由選自由以下組成之群之方法投與:經口、經直腸、皮下、經鼻、經頰及舌下。 在某些實施例中,本發明提供以上醫藥組合物,其包含選自由以下組成之群之載劑:乳糖、澱粉、葡萄糖、甲基纖維素、硬脂酸鎂、甘露醇及山梨醇。 在某些實施例中,本發明提供以上醫藥組合物,其包含選自由以下組成之群之稀釋劑:乙醇、甘油及水。 在某些實施例中,本發明提供以上醫藥組合物,其包含選自由以下組成之群之賦形劑:澱粉、明膠、葡萄糖、無水乳糖、自由流動乳糖、β-乳糖、玉米甜味劑、阿拉伯樹膠、黃蓍膠、海藻酸鈉、羧甲基纖維素、聚乙二醇、油酸鈉、硬脂酸鈉、硬脂酸鎂、苯甲酸鈉、乙酸鈉及氯化鈉。 在某些實施例中,本發明提供以上醫藥組合物,其進一步包含防腐劑、抗氧化劑及穩定劑中之至少一者。 在某些實施例中,本發明提供以上醫藥組合物,其包含選自由以下組成之群之防腐劑:苯甲酸鈉、山梨酸及對羥基苯甲酸之酯。 在某些實施例中,本發明提供以上醫藥組合物,其中該細菌菌株經凍乾。 在某些實施例中,本發明提供以上醫藥組合物,其中當將組合物儲存在約4℃或約25℃下之密封容器中並將容器置於具有50%相對濕度之氣氛中時,在至少約1個月、3個月、6個月、1年、1.5年、2年、2.5年或3年之時間段後保留至少80%細菌菌株(如以菌落形成單位所量測)。 在一些實施例中,將本發明之組合物提供於包含如本文中所述組合物之密封容器中。在一些實施例中,密封容器係小藥囊或瓶子。在一些實施例中,將本發明之組合物提供於包含如本文中所述組合物之注射器中。 在一些實施例中,可將本發明之組合物作為醫藥調配物提供。舉例而言,可將組合物作為錠劑或膠囊提供。在一些實施例中,膠囊係明膠膠囊(「gel-cap」)。 在一些實施例中,本發明之組合物係經口投與。經口投與可涉及吞嚥(以使化合物進入胃腸道)及/或經頰、經舌或舌下投與,化合物藉由該方式自口腔直接進入血流。 適於經口投與之醫藥調配物包括固體栓塞、固體微粒、半固體及液體(包括多相或分散系統),例如錠劑;含有多顆粒或奈米顆粒之軟質或硬質膠囊、液體(例如,水溶液)、乳液或粉劑;菱形錠劑(包括液體填充的);咀嚼劑;凝膠劑;快速分散劑型;膜劑;陰道栓劑;噴霧劑;及頰/黏膜黏著貼片。 在一些實施例中,醫藥調配物係腸溶調配物,亦即適於藉由經口投與將本發明之組合物遞送至腸之胃耐受性調配物(舉例而言,耐受胃內pH)。當組合物之細菌或另一組份對酸敏感(例如,在胃內條件下易於降解)時,腸溶調配物可尤其有用。 在一些實施例中,腸溶調配物包含腸溶包衣。在一些實施例中,調配物係腸衣劑型。舉例而言,調配物可係腸衣錠劑或腸衣膠囊或諸如此類。腸溶包衣可係習用腸溶包衣,例如,用於經口遞送之錠劑、膠囊或諸如此類之習用包衣。調配物可包含膜包衣,例如,腸溶聚合物(例如,酸不溶性聚合物)之薄膜層。 在一些實施例中,腸溶調配物具固有腸溶性,例如,無需腸溶包衣即具胃耐受性。因此,在一些實施例中,調配物係不包含腸溶包衣之腸溶調配物。在一些實施例中,調配物係自熱膠凝材料製得之膠囊。在一些實施例中,熱膠凝材料係纖維素材料,例如甲基纖維素、羥甲基纖維素或羥丙基甲基纖維素(HPMC)。在一些實施例中,膠囊包含不含任何成膜聚合物之殼。在一些實施例中,膠囊包含殼且殼包含羥丙基甲基纖維素且不含任何成膜聚合物(例如參見[31])。在一些實施例中,調配物係固有腸溶性膠囊(例如Capsugel之Vcaps®)。 在一些實施例中,調配物係軟質膠囊。軟質膠囊係可因添加存在於膠囊殼中之軟化劑(例如甘油、山梨醇、麥芽糖醇及聚乙二醇)而具有一定彈性及柔軟性之膠囊。軟質膠囊可例如基於明膠或澱粉製造。基於明膠之軟質膠囊可自多個供應商購得。根據投與方法,例如經口或經直腸,軟質膠囊可具有各種形狀,其可係例如圓形、卵形、長橢圓形或魚雷形。軟質膠囊可藉由習用方法製造,例如藉由Scherer方法、Accogel方法或微滴或吹製方法。 培養方法
用於本發明中之細菌菌株可使用例如參考文獻[32-34]中詳述之標準微生物學技術培養。 用於培養之固體或液體培養基可係例如YCFA瓊脂或YCFA培養基。YCFA培養基可包括(每100ml,近似值):酪腖(Casitone,1.0 g)、酵母提取物(0.25 g)、NaHCO3
(0.4 g)、半胱胺酸(0.1 g)、K2
HPO4
(0.045 g)、KH2
PO4
(0.045 g)、NaCl (0.09 g)、(NH4
)2
SO4
(0.09 g)、MgSO4
· 7H2
O (0.009 g)、CaCl2
(0.009 g)、刃天青(0.1 mg)、氯化血紅素(1 mg)、生物素(1 μg)、鈷胺素(1 μg)、對胺基苯甲酸(3 μg)、葉酸(5 μg)及吡哆胺(15 μg)。 概述
除非另有指示,否則本發明實踐將採用熟習此項技術者已知之習用化學、生物化學、分子生物學、免疫學及藥理學方法。此等技術於文獻中充分解釋。參見例如參考文獻[35-42]等。
術語「包含」涵蓋「包括」以及「由……組成」,例如「包含」X之組合物可僅由X組成或可包括其他,例如X + Y。 與數值x
相關之術語「約」為可選且意指例如x
±10%。 詞語「實質上」不排除「完全」,例如「實質上不含」Y之組合物可完全不含Y。需要時,詞語「實質上」可自本發明之定義省略。 提及兩個核苷酸序列之間之序列一致性百分比時意指,當比對時,兩個序列之比較中該百分比之核苷酸相同。此比對及同源性或序列一致性百分比可使用業內已知軟體程式(例如,闡述於參考文獻[43]之章節7.7.18中之彼等)測定。較佳比對係藉由Smith-Waterman同源性檢索算法使用仿射空位檢索測定,其中空位開放罰分為12且空位延伸罰分為2,BLOSUM矩陣為62。Smith-Waterman同源性檢索算法係揭示於參考文獻[44]中。 除非明確說明,否則包含多個步驟之製程或方法可在方法開始或結束時包含額外步驟,或可包含額外中間步驟。而且,若適當,可將步驟組合、省略或以替代順序實施。 本文闡述本發明之多個實施例。應認識到,在每一實施例中所指定之特徵可與其他指定特徵組合,以提供其他實施例。特定而言,在本文中強調為適宜、典型或較佳之實施例可與彼此組合(除非其互斥)。實施本發明之模式 實例 1 - 細菌接種物在內臟過敏性之大鼠模型中之效能 概述
利用來自展現內臟過敏性之人類IBS個體之糞便微生物區接種大鼠。然後將包含本發明細菌菌株之組合物投與大鼠且然後使用擴張分析測試以量測內臟過敏性。發現本發明之組合物減少大鼠對擴張之反應,從而指示內臟過敏性之降低。 菌株
氫營養布勞特氏菌(BH)菌株DSM 10507/14294。 組合物及投與
BH培養物(16H)或凍乾物-藉由經口胃管灌食投與 藉由經口胃管灌食投與之對照溶液 大鼠
經來自IBS個體之人類腸微生物區接種。 研究設計
第14天-大鼠經來自IBS個體之人類腸微生物區接種 第0天至第28天-每天給予BH培養物或凍乾物或對照溶液 第0天、第14天及第28天-糞便試樣中BH群體之qPCR 第14天與第28天之間-操作以將電極植入腹部中(用於擴張分析) 第28天-擴張分析,收集盲腸試樣用於硫化物及短鏈脂肪酸(SCFA)分析,計數選擇性培養基上糞便試樣中之微生物區 結果
圖1呈現來自經投與對照溶液(IBS)或BH凍乾物(IBS+BH)之大鼠之糞便試樣中BH群體之qPCR分析的結果。第14天及第28天時在接受BH凍乾物之大鼠中觀察到BH群體增加,其證實移生成功。 圖2呈現擴張分析之結果。使大鼠經受結腸直腸擴張並記錄每分鐘之收縮數作為內臟過敏性之特定量度。經本發明組合物治療之大鼠展現減少之收縮及降低之內臟過敏性。 圖3及圖4報告投與BH培養物及凍乾物對糞便試樣中之微生物區之效應。投與BH培養物導致硫酸鹽還原細菌(SRB)顯著減少(1 log)。 圖5報告投與BH凍乾物對微生物區發酵之影響,如藉由盲腸試樣中之短鏈脂肪酸濃度所量測。投與BH凍乾物導致乙酸鹽產量增加。 圖6報告投與BH凍乾物對微生物區發酵之影響,如藉由盲腸試樣中之硫化物(H2
S)濃度所量測。投與BH導致硫化物產量減少。 結論
投與包含氫營養布勞特氏菌之組合物導致成功移生及內臟過敏性顯著降低,如使用擴張分析所量測。當將氫營養布勞特氏菌作為培養物及作為凍乾物投與時觀測到此效應。投與氫營養布勞特氏菌亦對微生物區構成及發酵具有顯著效應,其中觀測到SRB及硫化物產量減少。該等數據指示,氫營養布勞特氏菌可用於降低內臟過敏性,且尤其用於降低與IBS相關之內臟過敏性。內臟過敏性之降低可與所觀測到之SRB及硫化物產量之減少相關。 實例 2 - 細菌凍乾物在內臟過敏性之大鼠模型中之效能
實例1之觀測在使用氫營養布勞特氏菌(BH)菌株DSM 10507/14294之凍乾物及IBS之大鼠模型之進一步實驗中得到證實。如在圖7及圖8中所顯示,投與BH凍乾物提供腹腔收縮數因應擴張之統計學上顯著的減少,從而指示內臟過敏性之降低。此外,如在圖9及圖10中所顯示,投與BH凍乾物提供硫化物之統計學上顯著的減少。 實例 3 - 細菌凍乾物對健康大鼠之效應
研究投與氫營養布勞特氏菌(BH)菌株DSM 10507/14294之凍乾物對健康HIM大鼠之效應且結果報告於圖11-14中。關於實驗之其他細節係提供於以上對圖之說明中。圖11顯示在大鼠中BH之適當劑量係109
個細胞/天或更多。圖12顯示在該等實驗中,BH並未永久地移生於大鼠消化道。圖13顯示BH主要係發現於盲腸中。圖14顯示投與BH誘導乙酸鹽以及丁酸鹽產量增加。 實例 4 - 細菌凍乾物在內臟過敏性之大鼠模型中之效能
進一步研究投與氫營養布勞特氏菌(BH)菌株DSM 10507/14294之凍乾物對IBS之大鼠模型之效應。利用來自C-IBS (患便秘)或U-IBS (未定型)患者之糞便試樣接種無菌大鼠。大多數實驗係利用來自顯示內臟過敏性(利用恒壓器量測之VH)之IBS患者之糞便試樣實施。結果報告於圖15及圖16中且關於實驗之其他細節係提供於以上對圖之說明中。圖15證實投與BH凍乾物引起硫酸鹽還原細菌統計學上顯著減少。如所預期,亦觀測到BH之增加。圖16顯示BH投與誘導由IBS HIM大鼠所產生之H2
S之量統計學上顯著減少。腸道微生物區產生過多盲腸H2
S與內臟過敏性相關。 實例 5 - 在 I 期臨床試驗期間患者症狀之改變
進行I期臨床試驗,其中將氫營養布勞特氏菌(「Blautix」,以登錄號DSM 10507以及以登錄號DSM 14294寄存之菌株)投與患有刺激性腸症候群(IBS)之人類患者。在投藥期間(第1-16天)將Blautix投與患者,且導瀉期係第19-23天。發現Blautix安全且耐受良好。監測到四種症狀,其中之一係腹痛。研究記錄患者經歷該等症狀中之每一者之改良、不變抑或惡化。將來自經投與Blautix之患者的結果與使用經投與安慰劑之患者所得之彼等結果比較。在三個時間點監測症狀:第1天、第15/16天及研究結束時。結果顯示於圖17及圖18中。 當將患者在第16天報告之症狀與第1天之基線比較時,17名接受Blautix 之IBS患者中有82%報告症狀之改良(圖17)。症狀(其中之一係腹痛)之改良支持使用Blautix治療或預防內臟過敏性。值得注意的是,在研究開始時皆患有嚴重腹痛之患者3.02、3.17及3.24在第15/16天分別患有輕微、輕微及無腹痛。 50%之接受安慰劑的患者報告症狀之改良(圖17)。高安慰劑反應率係在IBS臨床研究中已確立之現象。最近基於顯著較小之相對於安慰劑之改良批准利福昔明(Xifaxan)治療IBS [45]。 基於本文呈現之教示,預期與投藥完成時(第16天)所呈現之症狀相比,在研究完成時(第19-23天)症狀惡化。在I期臨床試驗中觀察到此症狀惡化:41%之IBS患者在Blautix投藥停止後報告症狀之惡化(圖18)。因此,症狀(其中之一係腹痛)在Blautix投藥停止後之惡化亦支持使用Blautix治療或預防內臟過敏性。 實例 6 - 在人類微生物區相關大鼠 (HMA 大鼠 ) 模型中研究之氫營養布勞特氏菌對內臟過敏性之效能 概述
利用來自人類IBS個體之糞便微生物區接種20隻無菌大鼠之組(IBS-HMA大鼠)。使用來自3個不同IBS患者之糞便試樣實施三次連續實驗。利用健康個體(n=2個個體;2組健康-HMA大鼠)之糞便試樣接種另兩組大鼠(n=10)作為內臟敏感性對照。然後將包含本發明氫營養布勞特氏菌之細菌菌株之組合物投與一半IBS-HMA大鼠28天,而另一半動物接受對照溶液。投與28天後,使用結腸擴張分析測試所有HMA-大鼠以量測內臟敏感性。發現本發明之組合物減少IBS-HMA大鼠對擴張之反應,從而指示內臟過敏性降低,達到如在健康-HMA大鼠中所觀測之正常敏感性。 菌株
氫營養布勞特氏菌(BH)菌株DSM 10507T
/14294。 組合物及投與
將BH凍乾物懸浮於無菌礦物溶液中至1010
個細菌/ml之濃度。藉由經口胃管灌食每天將2 ml此懸浮液投與每隻IBS-HMA大鼠經28天之時期。 對照溶液係無菌礦物溶液,藉由經口胃管灌食將其每天投與(2 ml/大鼠)對照組之IBS-HMA大鼠。 大鼠
利用來自IBS個體之人類糞便微生物區接種無菌雄性Fisher大鼠(10週齡) (IBS-HMA大鼠)。利用相同的人類糞便接種物接種20隻大鼠。利用來自3個不同IBS個體之糞便試樣實施3次連續實驗。利用來自2個健康個體之糞便試樣接種另2組10隻大鼠(正常敏感性對照組)。 研究設計
第14天-利用人類糞便微生物區接種無菌大鼠。 第0天至第28天-藉由經口胃管灌食每天給予BH凍乾物(分析組)或對照溶液(對照組)。 第14天與第22天之間-操作以將電極植入腹部中(用於擴張分析)。 第22-28天-使大鼠適應以避免與擴張測試相關之壓力。 第28天-擴張分析並將動物安樂死以收集盲腸試樣用於硫化物及短鏈脂肪酸(SCFA)分析。 第0、14及28天-收集糞便試樣用於微生物分析:qPCR用於評估BH群體及其他共生微生物群,且使用選擇性培養基及嚴格嫌氧方法計數微生物之功能群。 結果 圖 19
呈現來自接受對照溶液或BH凍乾物之IBS-HMA大鼠之糞便試樣中氫營養布勞特氏菌群體之qPCR分析的結果。在投與時期結束時(第28天)在接受BH凍乾物之大鼠中觀測到BH群體顯著增加,其證實成功將BH遞送於結腸中。圖 20
呈現擴張分析之結果。使大鼠經受結腸直腸擴張並記錄每5分鐘之收縮數作為內臟過敏性之特定量度。經本發明組合物治療之IBS-HMA大鼠展現減少之收縮,此反映內臟過敏性之降低。氫營養布勞特氏菌治療後,與在健康HMA大鼠中所量測者相比,IBS-HMA大鼠顯示正常內臟敏感性。在圖20中所顯示之BlautiX治療組內之3隻大鼠與圖8中所顯示之彼等相同。圖 21
報告投與氫營養布勞特氏菌對來自糞便微生物區之一些微生物組之效應,先前發現該等微生物組在IBS患者中受影響。投與BH導致硫酸鹽還原細菌(SRB)顯著減少。圖 22
報告投與BH對IBS-HMA大鼠之盲腸試樣中硫化物(H2
S)濃度之影響。投與BH導致硫化物產量顯著減少。在圖22中所顯示之BlautiX治療組內之3隻大鼠與在圖10中所顯示之彼等相同。圖 23
報告投與BH對IBS-HMA大鼠之盲腸試樣中之主要發酵代謝物(短鏈脂肪酸)之影響。投與BH導致乙酸鹽濃度顯著增加以及丁酸鹽濃度顯著增加(圖23B)。 結論
投與包含氫營養布勞特氏菌之組合物引起內臟過敏性顯著降低,如使用擴張分析所量測。治療後,發現IBS-HMA大鼠之內臟敏感性與在健康-HMA大鼠中所量測者相似。投與包含氫營養布勞特氏菌之組合物可使IBS-HMA動物之內臟敏感性恢復至正常。投與氫營養布勞特氏菌亦對微生物區構成及發酵具有顯著效應,且尤其誘導SRB及硫化物產量顯著減少。該等數據指示,氫營養布勞特氏菌可用於降低內臟過敏性,且尤其用於降低與IBS相關之內臟過敏性。內臟過敏性之降低可與所觀測到的SRB及硫化物產量之減少相關。 實例 7 - 穩定性測試
將含有至少一種本文中所述之細菌菌株之本文中所述之組合物儲存於25℃或4℃下之密封容器中並將容器置於具有30%、40%、50%、60%、70%、75%、80%、90%或95%之相對濕度之氣氛中。1個月、2個月、3個月、6個月、1年、1.5年、2年、2.5年或3年後,應保留至少50%、60%、70%、80%或90%之細菌菌株,如以藉由標準方案測定之菌落形成單位所量測。序列
SEQ ID NO:1 (糞便布勞特氏菌菌株GAM6-1 16S核糖體RNA基因,部分序列- HM626177) 1 tgcaagtcga gcgaagcgct tacgacagaa ccttcggggg aagatgtaag ggactgagcg 61 gcggacgggt gagtaacgcg tgggtaacct gcctcataca gggggataac agttggaaac 121 ggctgctaat accgcataag cgcacggtat cgcatgatac agtgtgaaaa actccggtgg 181 tatgagatgg acccgcgtct gattagctag ttggaggggt aacggcccac caaggcgacg 241 atcagtagcc ggcctgagag ggtgaacggc cacattggga ctgagacacg gcccagactc 301 ctacgggagg cagcagtggg gaatattgca caatggggga aaccctgatg cagcgacgcc 361 gcgtgaagga agaagtatct cggtatgtaa acttctatca gcagggaaga aaatgacggt 421 acctgactaa gaagccccgg ctaactacgt gccagcagcc gcggtaatac gtagggggca 481 agcgttatcc ggatttactg ggtgtaaagg gagcgtagac ggaagagcaa gtctgatgtg 541 aaaggctggg gcttaacccc aggactgcat tggaaactgt ttttcttgag tgccggagag 601 gtaagcggaa ttcctagtgt agcggtgaaa tgcgtagata ttaggaggaa caccagtggc 661 gaaggcggct tactggacgg taactgacgt tgaggctcga aagcgtgggg agcaaacagg 721 attagatacc ctggtagtcc acgccgtaaa cgatgaatac taggtgttgg ggagcaaagc 781 tcttcggtgc cgcagcaaac gcaataagta ttccacctgg ggagtacgtt cgcaagaatg 841 aaactcaaag gaattgacgg ggacccgcac aagcggtgga gcatgtggtt taattcgaag 901 caacgcgaag aaccttacca agtcttgaca tcgatctgac cggttcgtaa tggaaccttt 961 ccttcgggac agagaagaca ggtggtgcat ggttgtcgtc agctcgtgtc gtgagatgtt 1021 gggttaagtc ccgcaacgag cgcaacccct atcctcagta gccagcaggt gaagctgggc 1081 actctgtgga gactgccagg gataacctgg aggaaggcgg ggacgacgtc aaatcatcat 1141 gccccttatg atttgggcta cacacgtgct acaatggcgt aaacaaaggg aagcgagccc 1201 gcgaggggga gcaaatccca aaaataacgt cccagttcgg actgcagtct gcaactcgac 1261 tgcacgaagc tggaatcgct agtaatcgcg aatcagaatg tcgcggtgaa tacgttcccg 1321 ggtcttgtac acaccgcccg tcacaccatg ggagtcagta acgcccgaag tc SEQ ID NO:2 (魏氏布勞特氏菌菌株WAL 14507 16S核糖體RNA基因,部分序列- EF036467) 1 caagtcgaac gggaattant ttattgaaac ttcggtcgat ttaatttaat tctagtggcg 61 gacgggtgag taacgcgtgg gtaacctgcc ttatacaggg ggataacagt cagaaatggc 121 tgctaatacc gcataagcgc acagagctgc atggctcagt gtgaaaaact ccggtggtat 181 aagatggacc cgcgttggat tagcttgttg gtggggtaac ggcccaccaa ggcgacgatc 241 catagccggc ctgagagggt gaacggccac attgggactg agacacggcc cagactccta 301 cgggaggcag cagtggggaa tattgcacaa tgggggaaac cctgatgcag cgacgccgcg 361 tgaaggaaga agtatctcgg tatgtaaact tctatcagca gggaagatag tgacggtacc 421 tgactaagaa gccccggcta actacgtgcc agcagccgcg gtaatacgta gggggcaagc 481 gttatccgga tttactgggt gtaaagggag cgtagacggt gtggcaagtc tgatgtgaaa 541 ggcatgggct caacctgtgg actgcattgg aaactgtcat acttgagtgc cggaggggta 601 agcggaattc ctagtgtagc ggtgaaatgc gtagatatta ggaggaacac cagtggcgaa 661 ggcggcttac tggacggtaa ctgacgttga ggctcgaaag cgtggggagc aaacaggatt 721 agataccctg gtagtccacg ccgtaaacga tgaataacta ggtgtcgggt ggcaaagcca 781 ttcggtgccg tcgcaaacgc agtaagtatt ccacctgggg agtacgttcg caagaatgaa 841 actcaaagga attgacgggg acccgcacaa gcggtggagc atgtggttta attcgaagca 901 acgcgaagaa ccttaccaag tcttgacatc cgcctgaccg atccttaacc ggatctttcc 961 ttcgggacag gcgagacagg tggtgcatgg ttgtcgtcag ctcgtgtcgt gagatgttgg 1021 gttaagtccc gcaacgagcg caacccctat cctcagtagc cagcatttaa ggtgggcact 1081 ctggggagac tgccagggat aacctggagg aaggcgggga tgacgtcaaa tcatcatgcc 1141 ccttatgatt tgggctacac acgtgctaca atggcgtaaa caaagggaag cgagattgtg 1201 agatggagca aatcccaaaa ataacgtccc agttcggact gtagtctgca acccgactac 1261 acgaagctgg aatcgctagt aatcgcggat cagaatgccg cggtgaatac gttcccgggt 1321 cttgtacaca ccgcccgtca caccatggga gtcagtaacg cccgaagtca gtgacctaac 1381 tgcaaagaag gagctgccga aggcgggacc gatgactggg gtgaagtcgt aacaaggt SEQ ID NO:3 (糞便布勞特氏菌菌株830之共有16S rRNA序列) TTTKGTCTGGCTCAGGATGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAGCGAAGCGCTTACGACAGAACCTTCGGGGGAAGATGTAAGGGACTGAGCGGCGGACGGGTGAGTAACGCGTGGGTAACCTGCCTCATACAGGGGGATAACAGTTGGAAACGGCTGCTAATACCGCATAAGCGCACAGTATCGCATGATACAGTGTGAAAAACTCCGGTGGTATGAGATGGACCCGCGTCTGATTAGCTAGTTGGAGGGGTAACGGCCCACCAAGGCGACGATCAGTAGCCGGCCTGAGAGGGTGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAAGGAAGAAGTATCTCGGTATGTAAACTTCTATCAGCAGGGAAGAAAATGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGAAGAGCAAGTCTGATGTGAAAGGCTGGGGCTTAACCCCAGGACTGCATTGGAAACTGTTTTTCTTGAGTGCCGGAGAGGTAAGCGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTACTGGACGGTAACTGACGTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAATACTAGGTGTTGGGGAGCAAAGCTCTTCGGTGCCGCAGCAAACGCAATAAGTATTCCACCTGGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTATTCGAAGCAACGCGAAGAACCTTACCAAGTCTTGACATCGATCTGACCGGTTCGTAATGGAACCTTTCCTTCGGGACAGAGAAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATCGTCAGTAGCCAGCAGGTAAAGCTGGGCACTCTGAGGAGACTGCCAGGGATAACCTGGAGGAAGGCGGGGACGACGTCAAATCATCATGCCCCTTATGATTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAGCCCGCGAGGGGGAGCAAATCCCAAAAATAACGTCCCAGTTCGGACTGCAGTCTGCAACTCGACTGCACGAAGCTGGAATCGCTAGTAATCGCGAATCAGAATGTCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTCAGTAACGCCCGAAGTCAGTGACCCAACCTTAGGGAGGGAGCTGCCGAAGGCGGGATTGATAACTGGGGTGAAGTCTAGGGGGT SEQ ID NO:4 (魏氏布勞特氏菌菌株MRX008之共有16S rRNA序列) TTCATTGAGACTTCGGTGGATTTAGATTCTATTTCTAGTGGCGGACGGGTGAGTAACGCGTGGGTAACCTGCCTTATACAGGGGGATAACAGTCAGAAATGGCTGCTAATACCGCATAAGCGCACAGAGCTGCATGGCTCAGTGTGAAAAACTCCGGTGGTATAAGATGGACCCGCGTTGGATTAGCTTGTTGGTGGGGTAACGGCCCACCAAGGCGACGATCCATAGCCGGCCTGAGAGGGTGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAAGGAAGAAGTATCTCGGTATGTAAACTTCTATCAGCAGGGAAGATAGTGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGTGTGGCAAGTCTGATGTGAAAGGCATGGGCTCAACCTGTGGACTGCATTGGAAACTGTCATACTTGAGTGCCGGAGGGGTAAGCGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTACTGGACGGTAACTGACGTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAATACTAGGTGTCNGGGGAGCATGGCTCTTCGGTGCCGTCGCAAACGCAGTAAGTATTCCACCTGGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAAGTCTTGACATCCGCCTGACCGATCCTTAACCGGATCTTTCCTTCGGGACAGGCGAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATCCTCAGTAGCCAGCATTTAAGGTGGGCACTCTGGGGAGACTGCCAGGGATAACCTGGAGGAAGGCGGGGATGACGTCAAATCATCATGCCCCTTATGATTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAGATCGTGAGATGGAGCAAATCCCAAAAATAACGTCCCAGTTCGGACTGTAGTCTGCAACCCGACTACACGAAGCTGGAATCGCTAGTAATCGCGGATCAGAATGCCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTCAGTAACGCCCGAAGTCAGTGACCTAACTGCAAAGAAGGAGCTGCCGAA SEQ ID NO:5 (氫營養布勞特氏菌菌株S5a36 16S核糖體RNA基因,部分序列- X95624.1) 1 gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac gaagcgatag agaacggaga 61 tttcggttga agttttctat tgactgagtg gcggacgggt gagtaacgcg tgggtaacct 121 gccctataca gggggataac agttagaaat gactgctaat accgcataag cgcacagctt 181 cgcatgaagc ggtgtgaaaa actgaggtgg tataggatgg acccgcgttg gattagctag 241 ttggtgaggt aacggcccac caaggcgacg atccatagcc ggcctgagag ggtgaacggc 301 cacattggga ctgagacacg gcccaaactc ctacgggagg cagcagtggg gaatattgca 361 caatggggga aaccctgatg cagcgacgcc gcgtgaagga agaagtatct cggtatgtaa 421 acttctatca gcagggaaga aagtgacggt acctgactaa gaagccccgg ctaattacgt 481 gccagcagcc gcggtaatac gtaaggggca agcgttatcc ggatttactg ggtgtaaagg 541 gagcgtagac ggtttggcaa gtctgatgtg aaaggcatgg gctcaacctg tggactgcat 601 tggaaactgt cagacttgag tgccggagag gcaagcggaa ttcctagtgt agcggtgaaa 661 tgcgtagata ttaggaggaa caccagtggc gaaggcggcc tgctggacgg taactgacgt 721 tgaggctcga aagcgtgggg agcaaacagg attagatacc ctggtagtcc acgctgtaaa 781 cgatgaatac taggtgtcgg gtggcaaagc cattcggtgc cgcagcaaac gcaataagta 841 ttcccacctg gggagtacgt tcgcaagaat gaaactcaaa ggaattgacg gggacccgca 901 caagcggtgg agcatgtggt ttaattcgaa gcaacgcgaa gaaccttacc aaatcttgac 961 atccctctga ccgggaagta atgttccctt ttcttcggaa cagaggagac aggtggtgca 1021 tggttgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcaacga gcgcaaccct 1081 tattcttagt agccagcagg tagagctggg cactctaggg agactgccag ggataacctg 1141 gaggaaggtg gggatgacgt caaatcatca tgccccttat gatttgggct acacacgtgc 1201 tacaatggcg taaacaaagg gaagcgaagg ggtgacctgg agcaaatctc aaaaataacg 1261 tctcagttcg gattgtagtc tgcaactcga ctacatgaag ctggaatcgc tagtaatcgc 1321 gaatcagaat gtcgcggtga atacgttccc gggtcttgta cacaccgccc gtcacaccat 1381 gggagtcagt aacgcccgaa gtcagtgacc caaccnaaag gagggagctg ccgaaggtgg 1441 gactgataac tggggtga參考文獻
[1] Spor等人(2011)Nat Rev Microbiol
. 9(4):279-90. [2] Eckburg等人(2005)Science
. 10;308(5728):1635-8. [3] Tap等人(2009),Environ Microbiol,
11(10):2574-84. [4] Macpherson等人(2001)Microbes Infect
. 3(12):1021-35 [5] Macpherson等人(2002)Cell Mol Life Sci.
59(12):2088-96. [6] Mazmanian等人(2005)Cell
15;122(1):107-18. [7] Frank等人(2007)PNAS
104(34):13780-5. [8] Scanlan等人 (2006)J Clin Microbiol
. 44(11):3980-8. [9] Kang等人(2010)Inflamm Bowel Dis
. 16(12):2034-42. [10] Machiels等人(2013)Gut
. 63(8):1275-83. [11] Lopetuso等人(2013), Gut Pathogens, 5: 23 [12] WO 2013/050792 [13] WO 03/046580 [14] WO 2013/008039 [15] WO 2014/167338 [16] Lee及Lee (2014)World J Gastroenterol.
20(27): 8886-8897. [17] Liu等人(2008)Int J Syst Evol Microbiol
58, 1896–1902. [18] Bernalier等人(1996)Arch. Microbiol
. 166 (3), 176-183. [19] Park等人(2012)Int J Syst Evol Microbiol.
62(Pt 4):776-9. [20] Masco等人(2003)Systematic and Applied Microbiology,
26:557-563. [21] Srůtková等人(2011)J. Microbiol. Methods
, 87(1):10-6. [22] Robinson及Gebhart (2008)Mol Interv
, 8(5): 242–253. [23] Zhou等人(2010)Pain.
148(3): 454–461. [24] Miyamoto-Shinohara等人(2008)J. Gen. Appl. Microbiol.
, 54, 9–24. [25] Cryopreservation及Freeze-Drying Protocols編輯,Day and McLellan, Humana Press. [26] Leslie等人(1995)Appl. Environ. Microbiol.
61, 3592–3597. [27] Mitropoulou等人(2013)J Nutr Metab
. (2013) 716861. [28] Kailasapathy等人(2002)Curr Issues Intest Microbiol.
3(2):39-48. [29] Handbook of Pharmaceutical Excipients,第二版(1994),由A Wade及PJ Weller編輯 [30] Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro編輯,1985) [31] US 2016/0067188 [32]Handbook of Microbiological Media ,
第四版(2010) Ronald Atlas, CRC Press. [33]Maintaining Cultures for Biotechnology and Industry
(1996) Jennie C. Hunter-Cevera, Academic Press [34] Strobel (2009)Methods Mol Biol
. 581:247-61. [35] Gennaro (2000)Remington: The Science and Practice of Pharmacy.
第20版,ISBN: 0683306472. [36]Molecular Biology Techniques: An Intensive Laboratory Course
, (Ream等人編輯,1998,Academic Press). [37]Methods In Enzymology
(S. Colowick及N. Kaplan編輯,Academic Press, Inc.) [38]Handbook of Experimental Immunology
,第I-IV卷(D.M. Weir及C.C. Blackwell編輯,1986,Blackwell Scientific Publications) [39] Sambrook等人(2001)Molecular Cloning: A Laboratory Manual
,第3版(Cold Spring Harbor Laboratory Press). [40]Handbook of Surface and Colloidal Chemistry
(Birdi, K.S.編輯,CRC Press,1997) [41] Ausubel等人(編輯) (2002)Short protocols in molecular biology
,第5版(Current Protocols). [42]PCR (Introduction to Biotechniques Series
),第2版,(Newton及Graham編輯,1997,Springer Verlag) [43]Current Protocols in Molecular Biology
(F.M. Ausubel等人編輯,1987) Supplement 30 [44] Smith及Waterman (1981)Adv. Appl. Math.
2: 482-489. [45] XIFAXAN- rifaximin tablet, Salix Pharmaceuticals, Inc. - FDA Highlights of Prescribing Information,於2015年11月經修訂
圖 1 :
藉由qPCR量測BH群體,其顯示接受BH凍乾物之動物在第14天及第28天時BH增加。圖 2 :
BH培養物及凍乾物對動物對擴張之反應的影響,其顯示接受BH組合物之動物收縮減少。圖 3 :
BH培養物對微生物區之影響,其顯示接受日劑量之BH培養物之大鼠中SRB減少1 log。圖 4 :
BH凍乾物對微生物區之影響。圖 5 :
BH凍乾物對微生物區發酵-短鏈脂肪酸之影響,其顯示經BH治療之大鼠中乙酸鹽產量增加。圖 6 :
BH凍乾物對微生物區發酵-硫化物之影響,其顯示硫化物產量之減少。圖 7 :
BH凍乾物對動物對擴張之反應之影響。大鼠MIH IBS + BH:CRD測試。圖 8 :
BH凍乾物對動物對擴張之反應之影響。大鼠MIH IBS + BH:所有數據-CRD測試。圖 9 :
BH凍乾物對硫化物之影響。大鼠MIH IBS + BH:硫化物濃度(mg/L)。圖 10 :
BH凍乾物對硫化物之影響。大鼠MIH IBS + BH:所有數據-硫化物濃度(mg/L)。圖 11 :
HIM大鼠中之投藥研究-接受不同濃度之細菌種的健康HIM大鼠之糞便試樣中氫營養布勞特氏菌(B. hydrogenotrophica
)之RT-PCR量化。圖 12 :
將氫營養布勞特氏菌經口投與(109
/天)健康HIM大鼠後之傳輸時間。圖 13 :
投與(以1010
/天/大鼠投與氫營養布勞特氏菌) 14天後,在健康HIM大鼠之糞便及盲腸試樣中發現之氫營養布勞特氏菌含量之比較(RT-PCR量化)。圖 14 :
氫營養布勞特氏菌(1010
/天,14天)對健康HIM大鼠之盲腸內容物中之短鏈脂肪酸產量(RMN1
H)之效應。圖 15 :
氫營養布勞特氏菌投與對IBS-HIM大鼠中之微生物群體之影響。圖 16 :
經氫營養布勞特氏菌治療(1010
/天,14天)之IBS-HIM大鼠中之硫化物產量。對照大鼠未經治療。圖 17 :
患者症狀在I期臨床試驗之投藥期間(第1-16天)之改變。圖 18 :
患者症狀在I期臨床試驗之導瀉期間之改變。圖 19 :
經或未經包含氫營養布勞特氏菌(BlautiX)之組合物治療28天之IBS-HMA大鼠之糞便試樣中的氫營養布勞特氏菌群體之qPCR評估。圖 20 :
在經或未經氫營養布勞特氏菌(BlautiX)治療28天之IBS-HMA大鼠中及在未經治療之健康HMA大鼠中對結腸直腸擴張之腹腔反應。圖 21 :
相對於對照溶液,氫營養布勞特氏菌(BlautiX)投與後,IBS HMA-大鼠糞便試樣中之細菌計數。圖 22 :
經或未經氫營養布勞特氏菌(Blautix)治療28天之IBS HMA-大鼠之盲腸試樣中之硫化物濃度。圖 23 :
經或未經氫營養布勞特氏菌(Blautix)治療28天之IBS-HMA大鼠之盲腸試樣中之短鏈脂肪酸(SCFA)濃度。圖 23A
顯示總SCFA濃度。圖 23B
顯示乙酸、丙酸及丁酸之濃度。
[主張利用生物材料1] TW中華民國;食品工業發展研究所生物資源保存及研究中心;2016/09/20;BCRC 910744 [主張利用生物材料2] TW中華民國;食品工業發展研究所生物資源保存及研究中心;2016/09/20;BCRC 910745 [主張利用生物材料3] GB英國;National Collections of Industria, Food and Marine Bacteria (NCIMB);2015/03/12;NCIMB 42381 [主張利用生物材料4] GB英國;National Collections of Industria, Food and Marine Bacteria (NCIMB);2015/11/16;NCIMB 42486
Claims (31)
- 一種包含布勞特氏菌(Blautia )屬之細菌菌株之組合物,其係用於治療或預防內臟過敏性之方法中。
- 如請求項1之組合物,其中該內臟過敏性與IBS、克隆氏病(Crohn’s disease)、潰瘍性結腸炎、功能性消化不良或嬰兒腸絞痛相關。
- 如請求項2之組合物,其中該內臟過敏性與IBS、克隆氏病、潰瘍性結腸炎或功能性消化不良相關。
- 如請求項1之組合物,其中該組合物係用於治療或預防經診斷患有IBS、克隆氏病、潰瘍性結腸炎、功能性消化不良或嬰兒腸絞痛之個體之內臟過敏性。
- 如請求項4之組合物,其中該組合物係用於治療或預防經診斷患有IBS、克隆氏病、潰瘍性結腸炎或功能性消化不良之個體之內臟過敏性。
- 如前述請求項中任一項之組合物,其中該組合物係用於內臟過敏性之治療或預防中減少硫酸鹽還原細菌(SRB)在胃腸道中之移生(colonisation)。
- 如前述請求項中任一項之組合物,其中該組合物係用於內臟過敏性之治療或預防中於胃腸道中降低H2 S含量或預防H2 S含量升高。
- 如前述請求項中任一項之組合物,其中該組合物係用於治療或預防遭受胃腸道、尤其結腸或直腸中脹痛之患者的內臟過敏性。
- 如前述請求項中任一項之組合物,其中該細菌菌株為氫營養布勞特氏菌(Blautia hydrogenotrophica )。
- 如請求項1至8中任一項之組合物,其中該細菌菌株為糞便布勞特氏菌(Blautia stercoris )。
- 如請求項1至8中任一項之組合物,其中該細菌菌株為魏氏布勞特氏菌(Blautia wexlerae )。
- 如請求項1至8中任一項之組合物,其中該細菌菌株具有與氫營養布勞特氏菌之細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。
- 如請求項12之組合物,其中該細菌菌株具有與SEQ ID NO:5至少97%、98%、99%、99.5%或99.9%一致之16s rRNA序列或具有SEQ ID NO:5之16s rRNA序列。
- 如請求項1至8中任一項之組合物,其中該細菌菌株具有與糞便布勞特氏菌之細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。
- 如請求項1至8中任一項之組合物,其中該細菌菌株具有與魏氏布勞特氏菌之細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。
- 如請求項1之組合物,其中該組合物包含氫營養布勞特氏菌種之細菌菌株,其用於治療或預防經診斷患有IBS之個體之內臟過敏性之方法中。
- 如請求項1之組合物,其中該組合物包含氫營養布勞特氏菌種之細菌菌株,其係用於內臟過敏性之治療或預防中減少硫酸鹽還原細菌(SRB)在胃腸道中之移生、在胃腸道中降低H2 S含量或預防H2 S含量升高。
- 如請求項1之組合物,其中該組合物包含糞便布勞特氏菌種之細菌菌株,其係用於治療或預防經診斷患有IBS之個體之內臟過敏性之方法中。
- 如請求項1之組合物,其中該組合物包含糞便布勞特氏菌種之細菌菌株,其係用於內臟過敏性之治療或預防中減少硫酸鹽還原細菌(SRB)在胃腸道中之移生、在胃腸道中降低H2 S含量或預防H2 S含量升高。
- 如請求項1之組合物,其中該組合物包含魏氏布勞特氏菌種之細菌菌株,其係用於治療或預防經診斷患有IBS之個體之內臟過敏性之方法中。
- 如請求項1之組合物,其中該組合物包含魏氏布勞特氏菌種之細菌菌株,其係用於內臟過敏性之治療或預防中減少硫酸鹽還原細菌(SRB)在胃腸道中之移生、在胃腸道中降低H2 S含量或預防H2 S含量升高。
- 如前述請求項中任一項之組合物,其中該組合物係用於經口投與。
- 如前述請求項中任一項之組合物,其中該組合物包含一或多種醫藥上可接受之賦形劑或載劑。
- 如前述請求項中任一項之組合物,其中該細菌菌株經凍乾。
- 如前述請求項中任一項之組合物,其中該細菌菌株有活力(viable)。
- 如前述請求項中任一項之組合物,其中該組合物包含布勞特氏菌屬之單一菌株。
- 如前述請求項中任一項之組合物,其包含該布勞特氏細菌菌株作為微生物菌群(microbial consortium)之部分。
- 一種包含如前述請求項中任一項之組合物之食物產品,其用於如前述請求項中任一項之用途。
- 一種包含如前述請求項中任一項之組合物之疫苗組合物,其用於如前述請求項中任一項之用途。
- 一種治療或預防內臟過敏性之方法,其包含將包含布勞特氏菌屬之細菌菌株之組合物投與需要之患者。
- 如請求項30之方法,其中該布勞特氏菌係氫營養布勞特氏菌。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1603817.6A GB201603817D0 (en) | 2016-03-04 | 2016-03-04 | Compositions comprising bacterial strains |
GBGB1612191.5A GB201612191D0 (en) | 2016-07-13 | 2016-07-13 | Compositions comprising bacterial strains |
GBGB1616022.8A GB201616022D0 (en) | 2016-07-13 | 2016-09-20 | Compositions comprising bacterial strains |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201733601A true TW201733601A (zh) | 2017-10-01 |
Family
ID=59742619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106107283A TW201733601A (zh) | 2016-03-04 | 2017-03-06 | 包含細菌菌株之組合物 |
Country Status (30)
Country | Link |
---|---|
US (4) | US10086022B2 (zh) |
EP (2) | EP3520801A1 (zh) |
JP (3) | JP6441536B2 (zh) |
KR (1) | KR102010207B1 (zh) |
CN (2) | CN108883139B (zh) |
AU (2) | AU2017226831B2 (zh) |
BR (1) | BR112018067689A2 (zh) |
CA (1) | CA3016179C (zh) |
CO (1) | CO2018010459A2 (zh) |
CY (1) | CY1122142T1 (zh) |
DK (1) | DK3313423T3 (zh) |
EA (1) | EA035949B1 (zh) |
ES (1) | ES2731579T3 (zh) |
HK (1) | HK1246670B (zh) |
HR (1) | HRP20191096T1 (zh) |
HU (1) | HUE044051T2 (zh) |
IL (2) | IL261371B (zh) |
LT (1) | LT3313423T (zh) |
MA (1) | MA42560B1 (zh) |
MD (1) | MD3313423T2 (zh) |
ME (1) | ME03487B (zh) |
MX (2) | MX2018010680A (zh) |
NZ (1) | NZ745678A (zh) |
PL (1) | PL3313423T3 (zh) |
PT (1) | PT3313423T (zh) |
RS (1) | RS58869B1 (zh) |
SG (2) | SG10201913557TA (zh) |
SI (1) | SI3313423T1 (zh) |
TW (1) | TW201733601A (zh) |
WO (1) | WO2017148596A1 (zh) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
SI3065748T1 (en) | 2014-12-23 | 2018-05-31 | 4D Pharma Research Limited | Severe bacteroid tethethioomycron and its use in reducing inflammation |
WO2016102951A1 (en) | 2014-12-23 | 2016-06-30 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
EA201890050A1 (ru) | 2015-06-15 | 2018-06-29 | 4Д Фарма Рисёрч Лимитед | Композиции, содержащие бактериальные штаммы |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
TWI797058B (zh) | 2015-06-15 | 2023-04-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
MX2017016560A (es) | 2015-06-15 | 2018-02-21 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas. |
MD3209310T2 (ro) | 2015-11-20 | 2018-06-30 | 4D Pharma Res Ltd | Compoziții care conțin tulpini bacteriene |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
TW201733601A (zh) | 2016-03-04 | 2017-10-01 | 4D製藥有限公司 | 包含細菌菌株之組合物 |
US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
TWI802545B (zh) * | 2016-07-13 | 2023-05-21 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
GB201621123D0 (en) * | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
CA3211208A1 (en) | 2017-04-03 | 2018-10-11 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
JP7212945B2 (ja) | 2017-05-22 | 2023-01-26 | フォーディー ファーマ リサーチ リミテッド | 細菌株を含む組成物 |
WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
AU2018283994B2 (en) | 2017-06-14 | 2021-03-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
SI3638271T1 (sl) | 2017-06-14 | 2021-01-29 | 4D Pharma Research Limited | Sestavki, ki vsebujejo bakterijske seve |
AU2019289190A1 (en) * | 2018-06-19 | 2021-01-07 | 4D Pharma Research Ltd | Dosage form comprising a live biotherapeutic product |
CN112566648A (zh) | 2018-07-16 | 2021-03-26 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
JP7228420B2 (ja) | 2019-03-13 | 2023-02-24 | 株式会社東芝 | 情報処理装置、情報処理方法、情報処理システム及びコンピュータプログラム |
CN114040986A (zh) | 2019-04-03 | 2022-02-11 | 4D制药科克有限公司 | 诊断疾病的方法 |
EA202193075A1 (ru) * | 2019-05-10 | 2022-02-17 | 4Д Фарма Рисерч Лимитед | Композиции, содержащие бактериальные штаммы |
WO2021044376A1 (en) * | 2019-09-05 | 2021-03-11 | White Dog Labs, Inc. | Mixotrophic probiotic compositions and uses thereof in the treatment of bloating |
KR102512643B1 (ko) * | 2020-10-28 | 2023-03-22 | 에코바이오홀딩스 주식회사 | 바이오황 함유 여액 분획물을 포함하는 알레르기성 질환의 예방, 개선 또는 치료용 조성물 |
WO2024062208A1 (en) * | 2022-09-20 | 2024-03-28 | Cost-Bry Pty Ltd (trading as BiomeBank) | Compositions and methods for reducing endogenous sulphide in inflammatory bowel diseases |
Family Cites Families (356)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
NL8300698A (nl) | 1983-02-24 | 1984-09-17 | Univ Leiden | Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten. |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
DK122686D0 (da) | 1986-03-17 | 1986-03-17 | Novo Industri As | Fremstilling af proteiner |
FR2613624B1 (fr) | 1987-04-10 | 1990-11-23 | Roussy Inst Gustave | Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines |
US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
CA1333564C (en) | 1988-08-02 | 1994-12-20 | Thomas Julius Borody | Treatment of gastro-intestinal disorders |
KR100225087B1 (ko) | 1990-03-23 | 1999-10-15 | 한스 발터라벤 | 피타아제의 식물내 발현 |
JP3110452B2 (ja) | 1990-05-09 | 2000-11-20 | ノボ ノルディスク アクティーゼルスカブ | エンドグルカナーゼ酵素を含んでなるセルラーゼ調製物 |
GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
US5443951A (en) | 1992-07-20 | 1995-08-22 | Kabushiki Kaisha Yakult Honsha | Species-specific oligonucleotides for bifidobacteria and a method of detection using the same |
ATE219143T1 (de) | 1992-12-10 | 2002-06-15 | Dsm Nv | Herstellung von heterologen proteinen in filamentösen fungi |
US5741665A (en) | 1994-05-10 | 1998-04-21 | University Of Hawaii | Light-regulated promoters for production of heterologous proteins in filamentous fungi |
US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
AUPM823094A0 (en) | 1994-09-16 | 1994-10-13 | Goodman Fielder Limited | Probiotic compositions |
AUPM864894A0 (en) | 1994-10-07 | 1994-11-03 | Borody, Thomas Julius | Treatment of bowel-dependent neurological disorders |
RU2078815C1 (ru) | 1995-01-17 | 1997-05-10 | Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского | Штамм бактерий bifidobacterium breve, используемый для получения бактерийных лечебно-профилактических бифидосодержащих препаратов |
JPH08259450A (ja) | 1995-03-17 | 1996-10-08 | Nichinichi Seiyaku Kk | インターフェロン産生増強剤 |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
AUPN698495A0 (en) | 1995-12-06 | 1996-01-04 | Pharma Pacific Pty Ltd | Improved therapeutic formulation and method |
SE508045C2 (sv) | 1996-02-26 | 1998-08-17 | Arla Ekonomisk Foerening | Adhesionsinhibitorer, preparat innehållande desamma och förfarande för framställning därav |
ATE407700T1 (de) | 1996-03-20 | 2008-09-15 | Univ New South Wales | Veränderung der mikrobenflora im verdauungstrakt |
AUPN881396A0 (en) | 1996-03-20 | 1996-04-18 | Arnott's Biscuits Limited | Enhancement of microbial colonization of the gastrointestinal tract |
ATE317005T1 (de) | 1996-03-27 | 2006-02-15 | Novozymes As | Alkaline-phosphatase-defiziente, filamentöse pilze |
US6033864A (en) | 1996-04-12 | 2000-03-07 | The Regents Of The University Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
WO1998043081A1 (en) | 1997-03-26 | 1998-10-01 | Ligand Pharmaceuticals Incorporated | Treatment of gastrointestinal disease with ppar modulators |
SE511524C2 (sv) | 1997-06-02 | 1999-10-11 | Essum Ab | Lactobacillus casei rhamnosus-stam samt farmaceutisk beredning för bekämpning av patogena tarmbakterier |
US5925657A (en) | 1997-06-18 | 1999-07-20 | The General Hospital Corporation | Use of PPARγ agonists for inhibition of inflammatory cytokine production |
AUPO758297A0 (en) | 1997-06-27 | 1997-07-24 | Rowe, James Baber | Control of acidic gut syndrome |
US5951977A (en) | 1997-10-14 | 1999-09-14 | The United States Of America, As Represented By The Secretary Of Agriculture | Competitive exclusion culture for swine |
IT1298918B1 (it) | 1998-02-20 | 2000-02-07 | Mendes Srl | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
DE19826928A1 (de) | 1998-06-17 | 1999-12-23 | Novartis Consumer Health Gmbh | Arzneimittel, lebensfähige anaerobe Bakterien enthaltend, die die Sulfatreduktion sulfatreduzierender Bakterien hemmen |
ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
US7090973B1 (en) | 1999-04-09 | 2006-08-15 | Oscient Pharmaceuticals Corporation | Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics |
CA2382966A1 (en) | 1999-08-27 | 2001-03-08 | Eli Lilly And Company | Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
CN101238853A (zh) | 2000-02-08 | 2008-08-13 | Dsmip资产公司 | 酸-稳定性蛋白酶在动物饲料中的用途 |
FR2808689B1 (fr) | 2000-05-11 | 2004-09-03 | Agronomique Inst Nat Rech | Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs |
US20020013270A1 (en) | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
JP2004536557A (ja) | 2000-11-27 | 2004-12-09 | ワシントン・ユニバーシティ | 哺乳動物の腸に対する共生ミクロフローラの効果を調べるための方法およびそれに基づく胃腸関連疾患の治療 |
DE10101793A1 (de) | 2001-01-17 | 2002-08-01 | Manfred Nilius | Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen |
EP1227152A1 (en) | 2001-01-30 | 2002-07-31 | Société des Produits Nestlé S.A. | Bacterial strain and genome of bifidobacterium |
KR100437497B1 (ko) | 2001-03-07 | 2004-06-25 | 주식회사 프로바이오닉 | 로타바이러스 및 유해 미생물 억제 활성을 가지는 신규내산성 락토바실러스 루테리 프로바이오-16 및 이를함유하는 생균활성제 |
EP1243273A1 (en) | 2001-03-22 | 2002-09-25 | Societe Des Produits Nestle S.A. | Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters |
DE60141773D1 (de) | 2001-04-20 | 2010-05-20 | Inst Systems Biology | Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren |
EP1260227A1 (en) | 2001-05-23 | 2002-11-27 | Societe Des Produits Nestle S.A. | Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria |
US20030092163A1 (en) | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
CA2457092A1 (en) | 2001-09-05 | 2003-03-20 | Vsl Pharmaceuticals, Inc. | Lactic acid bacteria comprising unmethylated cytosine-guanine dinucleotides for use in therapy |
GB0127916D0 (en) | 2001-11-21 | 2002-01-16 | Rowett Res Inst | Method |
WO2003045317A2 (en) | 2001-11-27 | 2003-06-05 | Washington University | Therapeutic protein and treatments |
EP1581119B1 (en) | 2001-12-17 | 2013-01-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
US7101565B2 (en) | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
DE10206995B4 (de) | 2002-02-19 | 2014-01-02 | Orthomol Pharmazeutische Vertriebs Gmbh | Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika |
JP2003261453A (ja) | 2002-03-11 | 2003-09-16 | Nippon Berumu Kk | E.フェカリスからなる抗腫瘍剤及び放射線防護剤 |
NZ537706A (en) | 2002-06-28 | 2008-03-28 | Puleva Biotech Sa | Probiotic microbial strains, comprising non-pathogenic strains which are capable of surviving in and being transferred to breast milk and/or amniotic fluid after oral intake in healthy individuals without colonizing other internal organs except mucousas |
US20040005304A1 (en) | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
GB0307026D0 (en) | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
EP1481681A1 (en) | 2003-05-30 | 2004-12-01 | Claudio De Simone | Lactic acid bacteria combination and compositions thereof |
GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
AU2003247193A1 (en) | 2003-07-23 | 2005-02-04 | M.D.Lab Corp. | Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus |
US7485325B2 (en) | 2003-08-06 | 2009-02-03 | Gayle Dorothy Swain | Animal food supplement compositions and methods of use |
JP4683881B2 (ja) | 2003-08-27 | 2011-05-18 | 有限会社アーク技研 | 抗腫瘍活性剤 |
US8192733B2 (en) | 2003-08-29 | 2012-06-05 | Cobb & Associates | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
US20050163764A1 (en) | 2003-09-22 | 2005-07-28 | Yale University | Treatment with agonists of toll-like receptors |
GB0323039D0 (en) | 2003-10-01 | 2003-11-05 | Danisco | Method |
JP4740866B2 (ja) | 2003-10-24 | 2011-08-03 | ナムローゼ フェンノートシャップ ニュートリシア | 乳児向けシンバイオティック組成物 |
US20050239706A1 (en) | 2003-10-31 | 2005-10-27 | Washington University In St. Louis | Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject |
CN100421676C (zh) | 2003-12-17 | 2008-10-01 | 纽迪西亚公司 | 乳酸产生细菌和肺功能 |
ES2235642B2 (es) | 2003-12-18 | 2006-03-01 | Gat Formulation Gmbh | Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos. |
AU2005227320B2 (en) | 2004-03-22 | 2010-06-24 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, National Insitutes Of Health | Cellular and viral inactivation |
JP2007535924A (ja) | 2004-05-07 | 2007-12-13 | − グスタフ ユングレン、ハンス | ワクチン用アジュバントとしてのフラジェリンの使用 |
PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
US7638513B2 (en) | 2004-06-02 | 2009-12-29 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
CA2611377C (en) | 2004-06-07 | 2019-04-09 | Harold David Gunn | Bacterial compositions for the treatment of cancer |
EP1629850B2 (en) | 2004-08-24 | 2013-05-22 | N.V. Nutricia | Nutritional composition comprising indigestible transgalactooligosaccharides and digestible galactose saccharides |
US20060062742A1 (en) | 2004-09-21 | 2006-03-23 | The Procter & Gamble Company | Compositions for reduction of human malodor |
KR100468522B1 (ko) | 2004-10-12 | 2005-01-31 | 주식회사 프로바이오닉 | 코로나바이러스와 돼지 써코바이러스 2형의 생육을 억제하는 신규한 내산성 프로바이오틱 엔테로코커스훼시움 프로바이오-63 |
US20060115465A1 (en) | 2004-10-29 | 2006-06-01 | Macfarlane George | Treatment of gastrointestinal disorders |
ITMI20042189A1 (it) | 2004-11-16 | 2005-02-16 | Anidral Srl | Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale |
TR201820329T4 (tr) | 2005-02-28 | 2019-01-21 | Nutricia Nv | Probiyotik İçeren Besin Bileşimi |
US20090233888A1 (en) | 2005-03-23 | 2009-09-17 | Usc Stevens, University Of Southern California | Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth |
WO2006102350A1 (en) | 2005-03-23 | 2006-09-28 | Washington University In St. Louis | The use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota |
JP2006265212A (ja) | 2005-03-25 | 2006-10-05 | Institute Of Physical & Chemical Research | Il−21産生誘導剤 |
US20100233312A9 (en) | 2005-04-11 | 2010-09-16 | The Procter & Gamble Company | Compositions comprising probiotic and sweetener components |
EP1714660A1 (en) | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
WO2006114778A1 (en) | 2005-04-26 | 2006-11-02 | Teagasc- The Agriculture And Food Development Authority | Probiotic composition suitable for animals |
DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
US7572474B2 (en) | 2005-06-01 | 2009-08-11 | Mead Johnson Nutrition Company | Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants |
US8075934B2 (en) | 2008-10-24 | 2011-12-13 | Mead Johnson Nutrition Company | Nutritional composition with improved digestibility |
JP2007084533A (ja) | 2005-08-24 | 2007-04-05 | Prima Meat Packers Ltd | 免疫応答調節組成物及び該組成物を有効成分とする食品 |
US7625704B2 (en) | 2005-08-31 | 2009-12-01 | Fred Hutchinson Cancer Research Center | Methods and compositions for identifying bacteria associated with bacteria vaginosis |
DK1933869T3 (da) | 2005-09-01 | 2010-03-01 | Schering Corp | Anvendelse af IL-23- og IL-17-antagonister til behandling af autoimmun øjenbetændelsessygdom |
WO2007035057A1 (en) | 2005-09-23 | 2007-03-29 | Gwangju Institute Of Science And Technology | Composition for preventing or treating artritis comprising lactic acid bacteria and collangen as active ingredients |
EP1776877A1 (en) | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
EP1940243B1 (en) | 2005-10-24 | 2011-08-03 | Nestec S.A. | Dietary fiber formulation and method of administration |
JP2007116991A (ja) | 2005-10-28 | 2007-05-17 | Eternal Light General Institute Inc | 機能性食品 |
US7767420B2 (en) | 2005-11-03 | 2010-08-03 | Momenta Pharmaceuticals, Inc. | Heparan sulfate glycosaminoglycan lyase and uses thereof |
AU2006320604A1 (en) | 2005-12-01 | 2007-06-07 | Schering Corporation | Compounds for the treatment of inflammatory disorders and microbial diseases |
US8889149B2 (en) | 2006-02-16 | 2014-11-18 | Wayne State University | Use of flagellin to prevent and treat gram negative bacterial infection |
US20080260906A1 (en) | 2006-03-17 | 2008-10-23 | Marko Stojanovic | Compositions comprising probiotic and sweetener components |
JP5031249B2 (ja) | 2006-03-22 | 2012-09-19 | 学校法人北里研究所 | 炎症抑制作用のある菌体含有組成物 |
CA2652559A1 (en) | 2006-05-18 | 2007-11-29 | Biobalance Llc | Biotherapeutic compositions and uses thereof |
CA2655665A1 (en) | 2006-05-26 | 2007-12-06 | Nestec S.A. | Methods of use and nutritional compositions of touchi extract |
US20100028449A1 (en) | 2006-06-06 | 2010-02-04 | Satya Prakash | Fermented milk product and use thereof |
TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
EP2845496A1 (en) | 2006-08-04 | 2015-03-11 | SHS International Ltd. | Protein free formula with prebiotics |
WO2008031438A2 (en) | 2006-09-13 | 2008-03-20 | Region Hovedstaden V/Gentofte Hospital | Treatment of asthma, eczema and/or allergy using non-pathogenic organisms |
US20080069861A1 (en) | 2006-09-19 | 2008-03-20 | National Starch And Chemical Investment Holding Corporation | Probiotic/Non-Probiotic Combinations |
WO2008050209A1 (en) | 2006-10-27 | 2008-05-02 | Pfizer Products Inc. | Hydroxypropyl methyl cellulose hard capsules and process of manufacture |
US20080118473A1 (en) | 2006-11-01 | 2008-05-22 | The Procter & Gamble Company | Methods of treating a respiratory condition comprising probiotic treatment |
EP1920781B1 (en) | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
WO2008064489A1 (en) | 2006-12-01 | 2008-06-05 | Mcmaster University | Probiotics to inhibit inflammation |
WO2008076696A2 (en) | 2006-12-18 | 2008-06-26 | Washington University In St. Louis | The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder |
DE102006062250A1 (de) | 2006-12-22 | 2008-06-26 | Roland Saur-Brosch | Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden |
WO2008083157A2 (en) | 2006-12-29 | 2008-07-10 | Washington University In St. Louis | Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject |
JP2008195635A (ja) | 2007-02-09 | 2008-08-28 | Crossfield Bio Inc | 馬用乳酸菌製剤 |
CN101678053B (zh) | 2007-02-28 | 2015-12-16 | Mjn美国控股有限责任公司 | 用于治疗或预防全身性炎症的方法 |
GB2460781B (en) | 2007-03-28 | 2012-01-25 | Alimentary Health Ltd | Probiotic bifidobacterium strains |
MY146590A (en) | 2007-03-28 | 2012-08-30 | Alimentary Health Ltd | Probiotic bifidobacterium strains |
WO2008134450A2 (en) | 2007-04-24 | 2008-11-06 | Kemin Industries, Inc. | Broad-spectrum antibacterial and antifungal activity of lactobacillus johnsonii d115 |
EP1997499A1 (en) | 2007-05-31 | 2008-12-03 | Puleva Biotech, S.A. | Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis |
EP1997906A1 (en) | 2007-06-01 | 2008-12-03 | Friesland Brands B.V. | Lactobacillus |
EP1997905A1 (en) | 2007-06-01 | 2008-12-03 | Friesland Brands B.V. | Nucleic acid amplification |
EP1997907A1 (en) | 2007-06-01 | 2008-12-03 | Friesland Brands B.V. | Bifidobacteria |
WO2008153377A1 (en) | 2007-06-15 | 2008-12-18 | N.V. Nutricia | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
EP2522358B1 (en) | 2007-06-27 | 2016-11-09 | Laboratorios Ordesa, S.l. | Peptides against rotavirus infection |
US20110027348A1 (en) | 2007-08-27 | 2011-02-03 | Janos Feher | Composition and method inhibiting inflammation |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
US20100284979A1 (en) | 2007-10-01 | 2010-11-11 | University College Cork, National University Of Ireland, Cork | Modulation of Tissue Fatty Acid Composition of a Host by Human Gut Bacteria |
US8658153B2 (en) | 2007-10-20 | 2014-02-25 | Universite De Liege | Bifidobacterial species |
CA2740434C (en) | 2007-10-26 | 2017-11-07 | Brenda E. Moore | Probiotic compositions and methods for inducing and supporting weight loss |
WO2009059284A2 (en) | 2007-11-02 | 2009-05-07 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
EP2065048A1 (en) | 2007-11-30 | 2009-06-03 | Institut Pasteur | Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation |
CN101969966B (zh) | 2007-12-07 | 2013-05-08 | 努特里希亚公司 | 用于尘螨变态反应的双歧杆菌 |
WO2009079564A2 (en) | 2007-12-17 | 2009-06-25 | Emory University | Immunogenic compositions and methods of use thereof |
ES2343499B1 (es) | 2007-12-24 | 2011-06-10 | Consejo Superior De Investigaciones Cientificas | Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten. |
BRPI0908348A2 (pt) | 2008-02-06 | 2015-07-28 | Procter & Gamble | Métodos e kits de composições para acentuar a resposta imunológica a uma condição respiratória |
EP2103226A1 (en) | 2008-03-18 | 2009-09-23 | Friesland Brands B.V. | Long-life probiotic food product |
ES2594102T3 (es) | 2008-04-18 | 2016-12-15 | Vaxinnate Corporation | Mutantes por deleción de la flagelina y métodos para su uso |
WO2009138220A1 (en) | 2008-05-13 | 2009-11-19 | Glycotope Gmbh | Fermentation process |
MX2008006546A (es) | 2008-05-21 | 2009-11-23 | Sigma Alimentos Sa De Cv | Bifidobacteria productora de ácido fólico, composición alimenticia y uso de la bifidobacteria. |
CN102940652B (zh) | 2008-05-28 | 2015-03-25 | 青岛东海药业有限公司 | 两形真杆菌制剂及其应用 |
CN101590081A (zh) | 2008-05-28 | 2009-12-02 | 青岛东海药业有限公司 | 凸腹真杆菌和两形真杆菌制剂及其应用 |
US8586029B2 (en) | 2008-06-04 | 2013-11-19 | Trustees Of Dartmouth College | Prevention or treatment of immune-relevant disease by modification of microfloral populations |
EP2133088A3 (en) | 2008-06-09 | 2010-01-27 | Nestec S.A. | Rooibos and inflammation |
WO2009151315A1 (en) | 2008-06-13 | 2009-12-17 | N.V. Nutricia | Nutritional composition for infants delivered via caesarean section |
WO2009154463A2 (en) * | 2008-06-20 | 2009-12-23 | Stichting Top Institute Food And Nutrition | Butyrate as a medicament to improve visceral perception in humans |
EP2138186A1 (en) | 2008-06-24 | 2009-12-30 | Nestec S.A. | Probiotics, secretory IgA and inflammation |
WO2010002241A1 (en) | 2008-06-30 | 2010-01-07 | N.V. Nutricia | Nutritional composition for infants delivered via caesarean section |
KR101017448B1 (ko) | 2008-09-18 | 2011-02-23 | 주식회사한국야쿠르트 | 대장의 건강 증진 효능을 갖는 비피도박테리움 롱검 에이취와이8004 및 이를 유효성분으로 함유하는 제품 |
US8137718B2 (en) | 2008-09-19 | 2012-03-20 | Mead Johnson Nutrition Company | Probiotic infant products |
US20100074870A1 (en) | 2008-09-19 | 2010-03-25 | Bristol-Myers Squibb Company | Probiotic infant products |
KR101057357B1 (ko) | 2008-09-22 | 2011-08-17 | 광주과학기술원 | 유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물 |
US9603876B2 (en) | 2008-09-25 | 2017-03-28 | New York University | Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
JP2012510800A (ja) | 2008-12-05 | 2012-05-17 | ネステク ソシエテ アノニム | 低出生体重児において使用するための組成物 |
US20120107279A1 (en) | 2008-12-19 | 2012-05-03 | Nestec S.A. | Prevention and treatment of rotavirus diarrhoea |
IT1392672B1 (it) | 2009-01-12 | 2012-03-16 | Wyeth Consumer Healthcare S P A | Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina |
EP2772269A3 (en) | 2009-03-05 | 2015-01-14 | Abbvie Inc. | IL-17 binding proteins |
JP5710876B2 (ja) | 2009-03-26 | 2015-04-30 | クロスフィールドバイオ株式会社 | 新規ビフィドバクテリウム属微生物およびその利用 |
EP2427499A1 (en) | 2009-05-07 | 2012-03-14 | Tate&Lyle Ingredients France SAS | Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans |
EP2251022A1 (en) | 2009-05-11 | 2010-11-17 | Nestec S.A. | Non-replicating micro-organisms and their immune boosting effect |
EP2251020A1 (en) | 2009-05-11 | 2010-11-17 | Nestec S.A. | Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles |
EP2429538B1 (en) | 2009-05-11 | 2015-10-21 | Nestec S.A. | Non-replicating bifidobacterium longum ncc2705 and immune disorders |
KR20100128168A (ko) | 2009-05-27 | 2010-12-07 | 중앙대학교 산학협력단 | 공액 리놀레산 생산능이 우수한 신규한 균주 |
US20100311686A1 (en) | 2009-06-03 | 2010-12-09 | Kasper Lloyd H | Nutraceutical composition and methods for preventing or treating multiple sclerosis |
WO2010143940A1 (en) | 2009-06-12 | 2010-12-16 | N.V. Nutricia | Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages |
EP2443259A4 (en) | 2009-06-16 | 2012-10-10 | Univ Columbia | BIOMARKERS FOR AUTISM AND USES THEREOF |
WO2011005756A1 (en) | 2009-07-06 | 2011-01-13 | Puretech Ventures, Llc | Delivery of agents targeted to microbiota niches |
AU2010274941A1 (en) | 2009-07-24 | 2012-02-09 | Southwest Regional Pcr, Llc | Universal microbial diagnosis, detection, quantification, and specimen-targeted therapy |
ES2664724T3 (es) | 2009-08-18 | 2018-04-23 | Nestec S.A. | Composición nutricional que comprende cepas de Bifidobacterium longum y que reduce los síntomas de alergia alimentaria, especialmente en lactantes y niños |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
WO2011036539A1 (en) | 2009-09-23 | 2011-03-31 | Borody Thomas J | Therapy for enteric infections |
EP2308498A1 (en) | 2009-09-30 | 2011-04-13 | Nestec S.A. | Administration of Bifidobacterium breve during infancy to prevent inflammation later in life |
US20120238468A1 (en) | 2009-10-05 | 2012-09-20 | Aak Patent B.V. | Methods for diagnosing irritable bowel syndrome |
WO2011044208A1 (en) | 2009-10-06 | 2011-04-14 | Scott Dorfner | Antibiotic formulations providing reduced gastrointentestinal side effects |
ES2595444T3 (es) | 2009-11-11 | 2016-12-30 | Alimentary Health Limited | Cepa de Bifidobacterium probiótica |
WO2011075138A1 (en) | 2009-12-18 | 2011-06-23 | Hill's Pet Nutrition, Inc. | Pet food compositions including probiotics and methods of manufacture and use thereof |
US20150104418A1 (en) | 2014-12-18 | 2015-04-16 | Microbios, Inc. | Bacterial composition |
FR2955774A1 (fr) | 2010-02-02 | 2011-08-05 | Aragan | Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation |
NL2004200C2 (en) | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides in weight management. |
NL2004201C2 (en) | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides to modulate the immune system. |
IT1398553B1 (it) | 2010-03-08 | 2013-03-01 | Probiotical Spa | Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario. |
JP5737646B2 (ja) | 2010-03-24 | 2015-06-17 | 森下仁丹株式会社 | 抗アレルギー剤 |
WO2011121379A1 (en) | 2010-03-30 | 2011-10-06 | Assistance Publique - Hopitaux De Paris | Use of bifidobacteria for preventing allergy in breastfed infants |
US8951512B2 (en) | 2010-05-04 | 2015-02-10 | New York University | Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota |
WO2011149335A1 (en) | 2010-05-25 | 2011-12-01 | N.V. Nutricia | Immune imprinting nutritional composition |
KR20130086155A (ko) | 2010-06-01 | 2013-07-31 | 무어 리서치 엔터프라이지스 엘엘씨 | 박테로이데스로부터의 세포 성분, 그의 조성물, 및 박테로이데스 또는 그의 세포 성분을 이용하는 치료 방법 |
WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性t細胞の増殖または集積を誘導する作用を有する組成物 |
TWI417054B (zh) | 2010-06-15 | 2013-12-01 | Jen Shine Biotechnology Co Ltd | 新穎糞腸球菌ljs-01及其益生用途 |
EP2397145A1 (en) | 2010-06-18 | 2011-12-21 | Nestec S.A. | L. johnsonii La1, B. longum NCC2705 and immune disorders |
FR2962045B1 (fr) | 2010-07-05 | 2012-08-17 | Bifinove | Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires |
TWI401086B (zh) | 2010-07-20 | 2013-07-11 | Univ China Medical | 胚芽乳酸桿菌及其用途 |
EP3235506B1 (en) | 2010-07-26 | 2023-12-06 | Qu Biologics Inc. | Immunogenic anti-inflammatory compositions |
US9308226B2 (en) | 2010-08-04 | 2016-04-12 | Thomas Julius Borody | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US9386793B2 (en) | 2010-08-20 | 2016-07-12 | New York University | Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota |
KR101250463B1 (ko) | 2010-10-12 | 2013-04-15 | 대한민국 | 신생아 분변에서 분리한 내산소성 비피도박테리움 롱검 비피더스 유산균 및 이를 이용한 프로바이오틱 조성물 |
EP2633074A1 (en) | 2010-10-27 | 2013-09-04 | Quantibact A/s | Capture of target dna and rna by probes comprising intercalator molecules |
CN102031235B (zh) | 2010-11-09 | 2012-07-25 | 中国农业大学 | 一种粪肠球菌anse228及其应用 |
EP2455092A1 (en) | 2010-11-11 | 2012-05-23 | Nestec S.A. | Non-replicating probiotic micro-organisms protect against upper respiratory tract infections |
US20120128644A1 (en) | 2010-11-24 | 2012-05-24 | Oragenics, Inc. | Use of Bacteria to Treat and Prevent Respiratory Infections |
CN102093967B (zh) | 2010-12-02 | 2013-01-30 | 中国农业科学院特产研究所 | 一株水貂源屎肠球菌及其应用 |
ES2389547B1 (es) | 2010-12-07 | 2013-08-08 | Consejo Superior De Investigaciones Científicas (Csic) | Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas. |
US9376473B2 (en) | 2011-01-10 | 2016-06-28 | Cleveland Biolabs, Inc. | Use of Toll-Like Receptor agonist for treating cancer |
PT2481299T (pt) | 2011-01-31 | 2017-03-08 | Synformulas Gmbh | Estirpes de bifidobacterium bifidum para aplicação em doenças gastrointestinais |
JP5840368B2 (ja) | 2011-02-02 | 2016-01-06 | カルピス株式会社 | 関節炎予防改善用物質 |
WO2012108830A1 (en) | 2011-02-09 | 2012-08-16 | Lavivo Ab | Synbiotic compositions for restoration and reconstitution of gut microbiota |
EP4129312A1 (en) | 2011-03-09 | 2023-02-08 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
BRPI1100857A2 (pt) | 2011-03-18 | 2013-05-21 | Alexandre Eduardo Nowill | agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real |
WO2012140636A1 (en) | 2011-04-11 | 2012-10-18 | Alimentary Health Limited | A probiotic formulation |
WO2012142605A1 (en) | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
JP2014512388A (ja) | 2011-04-20 | 2014-05-22 | マイコ・バイオ,インコーポレーテッド | 免疫反応を増進するための組成物および方法 |
US9567361B2 (en) | 2011-05-13 | 2017-02-14 | Glycosyn LLC | Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics |
KR20120133133A (ko) | 2011-05-30 | 2012-12-10 | 한국 한의학 연구원 | 생약 추출물 또는 이의 유산균 발효물을 포함하는 호흡기 질환의 예방 또는 치료용 조성물 |
US20140171339A1 (en) | 2011-06-06 | 2014-06-19 | The University Of North Carolina At Chapel Hill | Methods and kits for detecting adenomas, colorectal cancer, and uses thereof |
GB201110095D0 (en) | 2011-06-15 | 2011-07-27 | Danisco | Method of treatment |
JP2013005759A (ja) | 2011-06-24 | 2013-01-10 | Kyodo Milk Industry Co Ltd | マウス腸内菌叢の推測方法 |
WO2013005836A1 (ja) | 2011-07-07 | 2013-01-10 | 長岡香料株式会社 | フルクトース吸収阻害剤 |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
US20130017999A1 (en) | 2011-07-14 | 2013-01-17 | Marc Fremont | Methods and Compositions for Evaluating and/or Treating Chronic Immune Diseases |
US20130022575A1 (en) | 2011-07-19 | 2013-01-24 | Microbial Rx | Systems and methods of replacing intestinal flora |
CN102304483A (zh) | 2011-08-12 | 2012-01-04 | 北京金泰得生物科技股份有限公司 | 一株饲用屎肠球菌及其应用 |
KR101261872B1 (ko) | 2011-08-23 | 2013-05-14 | 대한민국 (식품의약품안전처장) | 장내 미생물 효소복합체 및 이의 제조방법 |
CA2848757C (en) | 2011-09-14 | 2021-11-09 | University Of Guelph | Methods to culture human gastrointestinal microorganisms |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
LT2750682T (lt) * | 2011-10-11 | 2016-10-10 | Achim Biotherapeutics Ab | Kompozicija, apimanti anaerobiškai auginamą žmogaus žarnyno mikroflorą |
CN103082292B (zh) | 2011-11-02 | 2015-03-04 | 深圳华大基因研究院 | 罗斯氏菌(Roseburia)在治疗和预防肥胖相关疾病中的应用 |
CN102373172B (zh) | 2011-11-03 | 2013-03-20 | 北京龙科方舟生物工程技术有限公司 | 一株屎肠球菌及其应用 |
CN104160014A (zh) | 2011-12-01 | 2014-11-19 | 国立大学法人东京大学 | 诱导调节性t细胞的增殖或积累的人源细菌 |
ES2408279B1 (es) | 2011-12-15 | 2014-09-09 | Universidad De Las Palmas De Gran Canaria | Bacteria acido láctica probiótica |
ITBG20120010A1 (it) | 2012-02-24 | 2013-08-25 | Milano Politecnico | Dispositivo per l'addestramento chirurgico |
ITMI20120471A1 (it) | 2012-03-26 | 2013-09-27 | Giovanni Mogna | Composizione a base di ceppi di batteri bifidobacterium longum in grado di aiutare il prolungamento della vita |
JP5792105B2 (ja) | 2012-03-27 | 2015-10-07 | 森永乳業株式会社 | ラクト−n−ビオースiの製造方法 |
EP2832859B1 (en) | 2012-03-30 | 2018-07-25 | Ajinomoto Co., Inc. | Diabetes-inducible bacterium |
WO2013154826A2 (en) | 2012-04-11 | 2013-10-17 | Nestec Sa | Methods for diagnosing impending diarrhea |
GB201206599D0 (en) | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
MX2014012362A (es) | 2012-04-13 | 2015-05-07 | Trustees Boston College | Composición prebiótica y métodos de uso. |
DK2850202T3 (da) | 2012-05-18 | 2020-05-18 | Genome Res Ltd | Fremgangsmåder og grupper |
ES2436251B1 (es) | 2012-05-25 | 2014-10-08 | Consejo Superior De Investigaciones Científicas (Csic) | Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas. |
JP6436580B2 (ja) | 2012-06-04 | 2018-12-12 | ガウラブ アグラーワル, | クローン病および関連する状態および感染症を処置するための組成物および方法 |
CN102743420A (zh) | 2012-06-06 | 2012-10-24 | 上海交通大学 | 改善肠道菌群结构的方法及应用 |
WO2014001368A1 (en) | 2012-06-25 | 2014-01-03 | Orega Biotech | Il-17 antagonist antibodies |
EP2879523B1 (en) | 2012-07-31 | 2016-11-16 | Nestec S.A. | Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (ibd) |
WO2014019271A1 (en) | 2012-08-01 | 2014-02-06 | Bgi Shenzhen | Biomarkers for diabetes and usages thereof |
WO2014032108A1 (en) | 2012-08-29 | 2014-03-06 | Borody Thomas J | Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions |
CA2881656C (en) | 2012-08-29 | 2023-07-11 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
WO2014043593A2 (en) | 2012-09-13 | 2014-03-20 | Massachusetts Institute Of Technology | Programmable drug delivery profiles of tumor-targeted bacteria |
KR101473058B1 (ko) | 2012-09-19 | 2014-12-16 | 주식회사 쎌바이오텍 | 과민성 대장 증후군 예방 또는 치료용 조성물 |
CN103652322B (zh) | 2012-09-21 | 2016-02-10 | 临沂思科生物科技有限公司 | 一种含乳酸菌的复合益生菌饲料添加剂的制备方法 |
WO2014053608A1 (en) | 2012-10-03 | 2014-04-10 | Metabogen Ab | Identification of a person having risk for atherosclerosis and associated diseases by the person's gut microbiome and the prevention of such diseases |
FR2997091B1 (fr) | 2012-10-22 | 2016-05-06 | Fond Mediterranee Infection | Utilisation d'un compose antioxydant pour la culture de bacteries sensibles a la tension en oxygene |
WO2014070225A1 (en) | 2012-10-30 | 2014-05-08 | Deerland Enzymes, Inc. | Prebiotic compositions comprising one or more types of bacteriophage |
US20150290140A1 (en) | 2012-10-30 | 2015-10-15 | Nestec S.A. | Compositions comprising microparticles and probiotics to deliver a synergistic immune effect |
EP2914135A1 (en) | 2012-11-01 | 2015-09-09 | Rijksuniversiteit Groningen | Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract |
WO2014075745A1 (en) | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
WO2014082050A1 (en) | 2012-11-23 | 2014-05-30 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
CN104918624A (zh) | 2012-11-26 | 2015-09-16 | 托马斯·朱利叶斯·波洛迪 | 恢复排泄物微生物群的组合物及其制造和使用方法 |
BR112015013784A2 (pt) | 2012-12-12 | 2017-07-11 | Massachusetts Inst Technology | aplicação, manipulação e otimização de sistemas, métodos e composições para manipulação de sequência e aplicações terapêuticas |
JP6552965B2 (ja) | 2012-12-12 | 2019-07-31 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作のための改善された系、方法および酵素組成物のエンジニアリングおよび最適化 |
PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
US20140193464A1 (en) | 2013-01-08 | 2014-07-10 | Imagilin Technology, Llc | Effects of probiotics on humans and animals under environmental or biological changes |
EP3904502A3 (en) | 2013-02-04 | 2022-02-23 | Seres Therapeutics, Inc. | Compositions and methods |
EP3587558A3 (en) | 2013-02-04 | 2020-03-04 | Seres Therapeutics, Inc. | Methods of populating a gastrointestinal tract |
CA2940226A1 (en) | 2013-02-22 | 2014-08-28 | The Regents Of The University Of California | Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life |
MX2015011700A (es) | 2013-03-05 | 2016-07-20 | Univ Groningen | Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion. |
EP2971148A4 (en) | 2013-03-14 | 2016-08-17 | Seres Therapeutics Inc | METHODS OF DETECTING PATHOGENS AND ENRICHING FROM MATERIALS AND COMPOSITIONS |
WO2014152338A1 (en) | 2013-03-14 | 2014-09-25 | Kabadi Mohan | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
EP2967077A4 (en) | 2013-03-15 | 2016-09-14 | Seres Therapeutics Inc | MICROBIAL COMPOSITIONS AND ASSOCIATED METHODS BASED ON A NETWORK |
US9669059B2 (en) | 2013-03-15 | 2017-06-06 | University Of Florida Research Foundation, Incorporated | Butyrogenic bacteria as probiotics to treat clostridium difficile |
CN103142656A (zh) | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | 脆弱拟杆菌在制备防治结肠癌组合物中的应用 |
CN103156888A (zh) | 2013-03-18 | 2013-06-19 | 广州知光生物科技有限公司 | 脆弱拟杆菌在制备治疗炎症性肠病组合物中的应用 |
CN103146620A (zh) | 2013-03-25 | 2013-06-12 | 广州知光生物科技有限公司 | 具有益生菌特性的脆弱拟杆菌 |
JP2014196260A (ja) | 2013-03-29 | 2014-10-16 | 公立大学法人奈良県立医科大学 | 慢性閉塞性肺疾患の予防又は治療用組成物 |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
JP2016521284A (ja) | 2013-05-10 | 2016-07-21 | カリフォルニア インスティチュート オブ テクノロジー | 大腸ガンのプロバイオティクスによる防止および処置 |
US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
AU2014275025B2 (en) | 2013-06-05 | 2016-12-01 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US20160120915A1 (en) * | 2013-06-10 | 2016-05-05 | New York University | Methods for manipulating immune responses by altering microbiota |
WO2014200334A1 (en) | 2013-06-14 | 2014-12-18 | N.V. Nutricia | Synbiotic composition for treatment of infections in allergic patients |
WO2015003001A1 (en) | 2013-07-01 | 2015-01-08 | The Washington University | Methods for identifying supplements that increase gut colonization by an isolated bacterial species, and compositions derived therefrom |
WO2015003305A1 (zh) | 2013-07-08 | 2015-01-15 | 吉瑞高新科技股份有限公司 | 电子烟盒 |
US9764019B2 (en) | 2013-07-09 | 2017-09-19 | Vedanta Biosciences, Inc. | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
CN105407728A (zh) | 2013-07-21 | 2016-03-16 | 霍勒拜欧姆公司 | 用于微生物组表征、监测和治疗的方法和系统 |
EP3027058B1 (en) | 2013-07-31 | 2020-07-15 | Incredible Foods, Inc. | Encapsulated functional food compositions |
WO2015021936A1 (en) | 2013-08-16 | 2015-02-19 | The University Of Hong Kong | Method and compositions for treating cancer using probiotics cross-reference to related application |
CN103509741B (zh) | 2013-08-22 | 2015-02-18 | 河北农业大学 | 布劳特菌auh-jld56及其在牛蒡苷元转化中的应用 |
WO2015038731A1 (en) | 2013-09-12 | 2015-03-19 | The Johns Hopkins University | Biofilm formation to define risk for colon cancer |
RU2016116954A (ru) | 2013-10-18 | 2017-11-23 | ИнноваЧайлдфуд АБ | Сбалансированный по пищевой ценности комбинированный пищевой продукт для детей раннего возраста и маленьких детей и способ изготовления указанного продукта |
PL229020B1 (pl) | 2013-11-13 | 2018-05-30 | Inst Biotechnologii Surowic I Szczepionek Biomed Spolka Akcyjna | Nowy szczep Bifidobacterium breve |
AU2014352643A1 (en) | 2013-11-25 | 2016-06-30 | Seres Therapeutics, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
WO2015095241A2 (en) | 2013-12-16 | 2015-06-25 | Seres Health, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
CN103981117B (zh) | 2013-12-24 | 2018-10-26 | 北京大伟嘉生物技术股份有限公司 | 一株高抗逆性屎肠球菌及其培养方法和应用 |
CN103981115B (zh) | 2013-12-24 | 2018-10-26 | 北京大伟嘉生物技术股份有限公司 | 一株高抗逆性屎肠球菌及其应用 |
CN103820363B (zh) | 2014-01-27 | 2016-02-24 | 福建省农业科学院生物技术研究所 | 一种屎肠球菌菌粉的制备与应用 |
CN103865846B (zh) | 2014-02-27 | 2016-03-30 | 扬州绿保生物科技有限公司 | 一种屎肠球菌及其制备方法 |
CN103849590B (zh) | 2014-03-25 | 2016-07-06 | 上海交通大学 | 一株耐酸短双歧杆菌BB8dpH及其应用 |
KR101683474B1 (ko) | 2014-03-26 | 2016-12-08 | 주식회사 쎌바이오텍 | 과민성 대장 증후군 예방 또는 치료용 조성물 |
US9783858B2 (en) | 2014-04-02 | 2017-10-10 | Northwestern University | Altered microbiome of chronic pelvic pain |
KR101583546B1 (ko) | 2014-04-09 | 2016-01-11 | 국립암센터 | 유전자 다형성을 이용한 소라페닙 치료에 대한 반응성 예측방법 |
MX2016013247A (es) | 2014-04-10 | 2017-05-03 | Riken | Composiciones y metodos para induccion de celulas th17. |
CN104195075B (zh) | 2014-08-14 | 2017-04-19 | 生合生物科技股份有限公司 | 一种屎肠球菌ef08及包含它的饲料添加物和饲料 |
WO2015168534A1 (en) | 2014-05-02 | 2015-11-05 | Novogy, Inc. | Therapeutic treatment of gastrointestinal microbial imbalances through competitive microbe displacement |
KR102312186B1 (ko) | 2014-05-08 | 2021-10-14 | 판옵테스 파르마 게스.엠.베.하. | 안 질환 및 장애 치료용 화합물 |
WO2016019506A1 (en) | 2014-08-05 | 2016-02-11 | BGI Shenzhen Co.,Limited | Use of eubacterium in the prevention and treatment for colorectal cancer related diseases |
US10925953B2 (en) | 2014-08-28 | 2021-02-23 | Yale University | Compositions and methods for treating an inflammatory disease or disorder |
US20160058808A1 (en) | 2014-09-03 | 2016-03-03 | California Institute Of Technology | Microbe-based modulation of serotonin biosynthesis |
CN104546934B (zh) | 2014-09-30 | 2019-04-09 | 深圳华大基因科技有限公司 | 粪副拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
CN104546940A (zh) | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 平常拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
CN104546933A (zh) | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 粪拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
CN104546935A (zh) | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 多形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
CN104546932A (zh) | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
CN104546942A (zh) | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 多氏拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
WO2016057671A1 (en) | 2014-10-07 | 2016-04-14 | University Of Virginia Patent Foundation | Compositions and methods for preventing and treating infection |
AU2015335601A1 (en) | 2014-10-24 | 2017-06-01 | Evolve Biosystems Inc. | Activated bifidobacteria and methods of use thereof |
EP3212289A4 (en) | 2014-10-30 | 2018-05-16 | California Institute of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
EP3998074A1 (en) | 2014-10-30 | 2022-05-18 | California Institute of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
JP6868562B2 (ja) | 2014-10-31 | 2021-05-19 | ペンデュラム セラピューティクス, インコーポレイテッド | 障害の微生物的処置および診断に関する方法および組成物 |
CN104435000A (zh) | 2014-11-12 | 2015-03-25 | 江南大学 | 乳酸菌对支气管哮喘治疗中的应用 |
EP3223835A4 (en) | 2014-11-25 | 2018-10-24 | Memorial Sloan-Kettering Cancer Center | Intestinal microbiota and gvhd |
MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
WO2016102951A1 (en) | 2014-12-23 | 2016-06-30 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
SI3065748T1 (en) | 2014-12-23 | 2018-05-31 | 4D Pharma Research Limited | Severe bacteroid tethethioomycron and its use in reducing inflammation |
CN104560820B (zh) | 2014-12-30 | 2017-10-20 | 杭州师范大学 | 屎肠球菌kq2.6及应用 |
CA2974510A1 (en) | 2015-01-23 | 2016-07-28 | Temple University-Of The Commonwealth System Of Higher Education | Use of short chain fatty acids in cancer prevention |
US9878177B2 (en) * | 2015-01-28 | 2018-01-30 | Elekta Ab (Publ) | Three dimensional localization and tracking for adaptive radiation therapy |
CN105982919A (zh) | 2015-02-26 | 2016-10-05 | 王汉成 | 生物减速剂抗癌技术 |
WO2016139217A1 (en) | 2015-03-04 | 2016-09-09 | Ab-Biotics, S.A. | Composition comprising anaerobically cultivated human intestinal microbiota |
US20160271189A1 (en) | 2015-03-18 | 2016-09-22 | Whole Biome, Inc. | Methods and compositions relating to microbial treatment and diagnosis of skin disorders |
US20180078587A1 (en) | 2015-03-18 | 2018-03-22 | Trustees Of Tufts College | Compositions and methods for preventing colorectal cancer |
MX2017015473A (es) | 2015-06-01 | 2018-08-15 | Univ Chicago | Tratamiento contra el cancer por manipulacion de la microflora comensal. |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
MX2017016560A (es) | 2015-06-15 | 2018-02-21 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas. |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
TWI797058B (zh) | 2015-06-15 | 2023-04-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
EA201890050A1 (ru) | 2015-06-15 | 2018-06-29 | 4Д Фарма Рисёрч Лимитед | Композиции, содержащие бактериальные штаммы |
CN105112333A (zh) | 2015-08-31 | 2015-12-02 | 江南大学 | 一种具有良好肠道定殖能力的长双歧杆菌及筛选方法和应用 |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
MD3209310T2 (ro) | 2015-11-20 | 2018-06-30 | 4D Pharma Res Ltd | Compoziții care conțin tulpini bacteriene |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
AU2016361583B2 (en) | 2015-11-25 | 2021-05-13 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization |
TW201733601A (zh) | 2016-03-04 | 2017-10-01 | 4D製藥有限公司 | 包含細菌菌株之組合物 |
TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
WO2018112365A2 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii |
WO2018112363A1 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Methods of treating cancer using parabacteroides |
WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
-
2017
- 2017-03-06 TW TW106107283A patent/TW201733601A/zh unknown
- 2017-03-06 CN CN201780014234.3A patent/CN108883139B/zh active Active
- 2017-03-06 BR BR112018067689A patent/BR112018067689A2/pt not_active Application Discontinuation
- 2017-03-06 ES ES17709911T patent/ES2731579T3/es active Active
- 2017-03-06 HU HUE17709911A patent/HUE044051T2/hu unknown
- 2017-03-06 PT PT17709911T patent/PT3313423T/pt unknown
- 2017-03-06 MA MA42560A patent/MA42560B1/fr unknown
- 2017-03-06 AU AU2017226831A patent/AU2017226831B2/en not_active Ceased
- 2017-03-06 KR KR1020187026243A patent/KR102010207B1/ko active IP Right Grant
- 2017-03-06 NZ NZ745678A patent/NZ745678A/en not_active IP Right Cessation
- 2017-03-06 PL PL17709911T patent/PL3313423T3/pl unknown
- 2017-03-06 WO PCT/EP2017/025038 patent/WO2017148596A1/en active Application Filing
- 2017-03-06 RS RS20190755A patent/RS58869B1/sr unknown
- 2017-03-06 SI SI201730045T patent/SI3313423T1/sl unknown
- 2017-03-06 EA EA201891970A patent/EA035949B1/ru unknown
- 2017-03-06 EP EP19161713.3A patent/EP3520801A1/en not_active Withdrawn
- 2017-03-06 CN CN202210349542.4A patent/CN114712405A/zh active Pending
- 2017-03-06 JP JP2018504969A patent/JP6441536B2/ja active Active
- 2017-03-06 MD MDE20180469 patent/MD3313423T2/ro unknown
- 2017-03-06 SG SG10201913557TA patent/SG10201913557TA/en unknown
- 2017-03-06 SG SG11201807195VA patent/SG11201807195VA/en unknown
- 2017-03-06 ME MEP-2019-175A patent/ME03487B/me unknown
- 2017-03-06 DK DK17709911.6T patent/DK3313423T3/da active
- 2017-03-06 MX MX2018010680A patent/MX2018010680A/es active IP Right Grant
- 2017-03-06 LT LTEP17709911.6T patent/LT3313423T/lt unknown
- 2017-03-06 CA CA3016179A patent/CA3016179C/en active Active
- 2017-03-06 EP EP17709911.6A patent/EP3313423B1/en active Active
-
2018
- 2018-03-08 US US15/916,167 patent/US10086022B2/en active Active
- 2018-03-08 US US15/916,202 patent/US10086023B2/en active Active
- 2018-05-14 HK HK18106239.8A patent/HK1246670B/zh unknown
- 2018-06-28 US US16/022,484 patent/US10583158B2/en active Active
- 2018-08-26 IL IL261371A patent/IL261371B/en active IP Right Grant
- 2018-09-04 MX MX2020005772A patent/MX2020005772A/es unknown
- 2018-09-11 AU AU2018229410A patent/AU2018229410B2/en not_active Ceased
- 2018-09-28 CO CONC2018/0010459A patent/CO2018010459A2/es unknown
- 2018-11-20 JP JP2018217285A patent/JP7160333B2/ja active Active
-
2019
- 2019-06-17 HR HRP20191096TT patent/HRP20191096T1/hr unknown
- 2019-07-08 CY CY20191100717T patent/CY1122142T1/el unknown
- 2019-12-18 IL IL271536A patent/IL271536B/en unknown
-
2021
- 2021-12-02 US US17/540,349 patent/US20220257667A1/en active Pending
-
2022
- 2022-06-06 JP JP2022091401A patent/JP2022116309A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220257667A1 (en) | Compositions comprising bacterial strains | |
US10967010B2 (en) | Compositions comprising bacterial strains | |
JP2022504185A (ja) | 細菌株を含む組成物 | |
US11224620B2 (en) | Compositions comprising bacterial strains | |
OA19461A (en) | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity. |